ovarian cancer (Cancer)

Search with Google Search with Bing
Information
Disease name
ovarian cancer
Disease ID
DOID:2394
Description
"A female reproductive organ cancer that is located_in the ovary." [url:http\://www.cancer.gov/dictionary?CdrID=445074]
Disease area statistics
Chromosome band
Gene symbol Chromosome Start Stop The number of variant
PMS2 7 5,970,957 6,009,122 186
MSH6 2 47,783,145 47,806,953 152
FBXO11 2 47,806,920 47,906,498 132
MSH2 2 47,403,156 47,483,223 116
TP53 17 7,668,421 7,687,490 44
EPCAM 2 47,369,311 47,387,020 32
MLH1 3 36,993,518 37,050,846 28
KCNK12 2 47,509,290 47,570,985 28
BRCA1 17 43,044,295 43,125,483 20
ARID1A 1 26,696,015 26,782,104 14
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT03382340 Active, not recruiting Phase 1/Phase 2 IMX-110 in Patients With Advanced Solid Tumors February 15, 2018 December 31, 2023
NCT03596281 Active, not recruiting Phase 1 Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer December 5, 2018 April 2023
NCT01439659 Active, not recruiting Phase 2 Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer February 18, 2003 March 1, 2026
NCT01081951 Active, not recruiting Phase 2 Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer February 4, 2010 December 31, 2024
NCT03246074 Active, not recruiting Phase 1 Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer April 3, 2018 October 1, 2024
NCT05840029 Active, not recruiting VATS IN PATIENTS WITH ADVANCED OVARIAN MALIGNANCIES June 1, 2021 April 30, 2023
NCT00657878 Active, not recruiting Phase 3 Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval November 2008 December 2023
NCT04511988 Active, not recruiting N/A Using Liquid Biopsy in Newly Diagnosed Patients With High Grade Adenocarcinoma of Ovarian Origin, Fallopian Tubes or Primary Peritoneal July 17, 2021 July 2026
NCT02043158 Active, not recruiting Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer January 16, 2014 December 30, 2026
NCT04116320 Active, not recruiting Phase 1 Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors November 21, 2019 February 2024
NCT04214964 Active, not recruiting Clinical Characters of the Diagnosis and Treatment of Gynecological Malignant Tumors in China : A Real World Study April 11, 2020 December 2024
NCT03891576 Active, not recruiting Phase 2 Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) November 13, 2019 December 31, 2024
NCT02321228 Active, not recruiting N/A Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers January 2015 January 2035
NCT04525183 Active, not recruiting N/A REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue December 2, 2020 December 28, 2023
NCT04570839 Active, not recruiting Phase 1/Phase 2 COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. August 31, 2020 August 2024
NCT01226316 Active, not recruiting Phase 1 Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules December 1, 2010 December 31, 2024
NCT03519230 Active, not recruiting Phase 3 Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer May 14, 2018 June 30, 2026
NCT04498117 Active, not recruiting Phase 3 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery August 25, 2020 August 26, 2027
NCT03249142 Active, not recruiting Phase 1/Phase 2 Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer October 18, 2017 December 31, 2024
NCT03836352 Active, not recruiting Phase 2 Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors December 21, 2018 December 31, 2023
NCT04248153 Active, not recruiting Phase 2 Optimal Timing of BR55 CEUS of the Ovaries October 14, 2019 March 31, 2024
NCT04625270 Active, not recruiting Phase 2 A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation December 21, 2020 December 2026
NCT04068896 Active, not recruiting Phase 1/Phase 2 Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy October 16, 2019 January 2025
NCT05483933 Active, not recruiting Phase 1 Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers August 18, 2022 April 2025
NCT03934827 Active, not recruiting Phase 1 MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour April 10, 2019 December 31, 2022
NCT03691012 Active, not recruiting Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer May 9, 2017 May 9, 2025
NCT05931445 Active, not recruiting N/A Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer January 26, 2021 March 31, 2027
NCT02873962 Active, not recruiting Phase 2 A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib November 10, 2016 July 2026
NCT05041257 Active, not recruiting Phase 2 Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) August 31, 2021 December 13, 2024
NCT04553133 Active, not recruiting Phase 1/Phase 2 PF-07104091 as a Single Agent and in Combination Therapy September 16, 2020 March 6, 2025
NCT02109367 Active, not recruiting Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass February 2014 June 2024
NCT05311618 Active, not recruiting Phase 1 Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors May 11, 2022 June 2025
NCT04853017 Active, not recruiting Phase 1 A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors October 4, 2021 March 2026
NCT02470299 Active, not recruiting N/A Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients October 29, 2015 October 8, 2025
NCT02828618 Active, not recruiting N/A Trial on Radical Upfront Surgery in Advanced Ovarian Cancer July 2016 February 2025
NCT05116189 Active, not recruiting Phase 3 Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) December 13, 2021 August 31, 2027
NCT00587886 Active, not recruiting Estrogen, Diet, Genetics and Endometrial Cancer September 25, 2001 December 31, 2024
NCT04051502 Active, not recruiting ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study August 5, 2019 August 2024
NCT02891824 Active, not recruiting Phase 3 ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab September 22, 2016 September 2024
NCT02869217 Active, not recruiting Phase 1 Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors September 2016 September 2024
NCT03614689 Active, not recruiting Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire November 25, 2017 June 2024
NCT04675320 Active, not recruiting Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors July 7, 2020 November 10, 2024
NCT06320418 Active, not recruiting The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer Progression June 15, 2022 June 2024
NCT03776630 Active, not recruiting N/A Exploring the Potential of Novel Biomarkers Based on Plasma microRNAs for a Better Management of Pelvic Gynecologic Tumors May 23, 2019 May 2027
NCT03667716 Active, not recruiting Phase 1 COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. September 6, 2018 May 31, 2024
NCT05693974 Active, not recruiting Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Retrospective Study) October 1, 2022 April 2023
NCT03532139 Active, not recruiting Phase 2 Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) July 25, 2018 May 31, 2024
NCT02562365 Active, not recruiting Phase 2 Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer November 2015 November 2023
NCT03907852 Active, not recruiting Phase 1/Phase 2 Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer April 15, 2019 November 2, 2028
NCT04152018 Active, not recruiting Phase 1 Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. November 13, 2019 August 30, 2024
NCT03054298 Active, not recruiting Phase 1 CAR T Cells in Mesothelin Expressing Cancers April 6, 2017 March 2025
NCT03363867 Active, not recruiting Phase 2 BEACON - ABC in Recurrent Platinum Resistant HGSOC July 10, 2018 June 30, 2025
NCT04227522 Active, not recruiting Phase 3 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients June 8, 2020 January 2025
NCT02854215 Active, not recruiting N/A Cost Utility of Radical Surgery in Ovarian Cancer January 18, 2017 June 2025
NCT02009449 Active, not recruiting Phase 1 A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors November 15, 2013 August 25, 2024
NCT05979298 Active, not recruiting Phase 2 Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer November 15, 2019 December 30, 2024
NCT00799110 Active, not recruiting Phase 2 Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod August 2008 December 2024
NCT04731467 Active, not recruiting Phase 1/Phase 2 A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors March 19, 2021 January 2025
NCT03877796 Active, not recruiting Clinical Pre-screening Protocol for Ovarian Cancer April 11, 2019 December 2024
NCT04739527 Active, not recruiting Phase 1 Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment June 10, 2021 June 1, 2026
NCT04024878 Active, not recruiting Phase 1 NeoVax With Nivolumab in Patients With Ovarian Cancer November 20, 2020 April 30, 2029
NCT03162289 Active, not recruiting N/A Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers May 10, 2017 June 10, 2025
NCT05368207 Active, not recruiting N/A Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient December 6, 2021 November 2, 2024
NCT05082025 Active, not recruiting Phase 2 Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations September 27, 2022 October 29, 2026
NCT03997968 Active, not recruiting Phase 1/Phase 2 A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors October 9, 2019 December 30, 2024
NCT05200364 Active, not recruiting Phase 1 A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer March 22, 2022 January 2026
NCT03225989 Active, not recruiting Phase 1/Phase 2 Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer March 1, 2018 August 22, 2024
NCT01767675 Active, not recruiting Phase 2 Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer January 8, 2013 January 2025
NCT04913337 Active, not recruiting Phase 1/Phase 2 Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies June 9, 2021 July 2025
NCT04470921 Active, not recruiting STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands January 1, 2019 December 31, 2025
NCT04454450 Active, not recruiting N/A Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer June 22, 2020 June 2025
NCT04729387 Active, not recruiting Phase 3 Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected July 2, 2021 January 31, 2026
NCT02568267 Active, not recruiting Phase 2 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) November 19, 2015 April 1, 2025
NCT04608409 Active, not recruiting Phase 1 Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer March 17, 2021 June 30, 2025
NCT03355976 Active, not recruiting Phase 2 BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas April 30, 2018 December 2025
NCT05305820 Active, not recruiting N/A Perioperative Exercise and Nutritional Optimisation Prehabilitation Before Surgery for Patients With Peritoneal Malignancy September 1, 2022 August 1, 2024
NCT03430700 Active, not recruiting Phase 2 Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer May 16, 2019 March 17, 2025
NCT03493464 Active, not recruiting Phase 2 BR55 in Characterization of Ovarian Lesions December 13, 2018 December 31, 2023
NCT05292859 Active, not recruiting Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs October 1, 2022 June 2039
NCT04931342 Active, not recruiting Phase 2 A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors October 7, 2021 December 31, 2028
NCT03748186 Active, not recruiting Phase 1 Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers February 1, 2019 November 2024
NCT03132922 Active, not recruiting Phase 1 MAGE-A4ᶜ¹º³²T for Multi-Tumor May 15, 2017 September 2032
NCT04908787 Active, not recruiting Phase 3 A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer June 11, 2021 December 2024
NCT05194735 Active, not recruiting Phase 1/Phase 2 Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors April 4, 2022 November 30, 2024
NCT04204811 Active, not recruiting Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy December 16, 2019 December 16, 2024
NCT02571725 Active, not recruiting Phase 1/Phase 2 PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer February 23, 2016 July 15, 2027
NCT03983954 Active, not recruiting Phase 1 Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors October 10, 2019 October 1, 2026
NCT03761914 Active, not recruiting Phase 1/Phase 2 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers June 28, 2019 April 30, 2023
NCT03561207 Active, not recruiting 3D Prediction of Patient-Specific Response June 11, 2018 December 2024
NCT02346747 Active, not recruiting Phase 2 A Trial of Vigil for Participants With Ovarian Cancer February 2015 December 2025
NCT00579488 Active, not recruiting Clinical Significance of Germline BRCA Mutations July 1996 July 2025
NCT04332653 Active, not recruiting Phase 1/Phase 2 NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors June 10, 2020 March 31, 2025
NCT02758652 Active, not recruiting Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer May 2016 May 2026
NCT04503265 Active, not recruiting Phase 1/Phase 2 A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies August 12, 2020 January 2025
NCT00326456 Active, not recruiting Phase 3 MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer January 1, 2003 December 2023
NCT02125513 Active, not recruiting Phase 2 Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer January 2014 December 2023
NCT00579514 Active, not recruiting N/A Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients March 2000 March 2025
NCT05256381 Active, not recruiting Phase 2 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors June 21, 2022 December 14, 2025
NCT00515372 Active, not recruiting Phase 1 Depression Treatment and Screening in Ovarian Cancer Patients December 20, 2002 December 31, 2027
NCT04724031 Active, not recruiting Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer November 1, 2019 September 30, 2023
NCT03170960 Active, not recruiting Phase 1/Phase 2 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors September 5, 2017 August 2024
NCT00660842 Active, not recruiting Phase 3 Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian Cancer November 2008 November 2024
NCT04234113 Active, not recruiting Phase 1 Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors June 13, 2019 November 2024
NCT06451263 Active, not recruiting N/A Nudge to Gynecologic Oncology January 19, 2024 May 31, 2025
NCT05348356 Active, not recruiting Phase 2 Nirogacestat in Ovarian Granulosa Cell Tumors August 30, 2022 December 2027
NCT03797326 Active, not recruiting Phase 2 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) February 12, 2019 December 20, 2024
NCT05652283 Active, not recruiting Phase 2 Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer November 6, 2022 May 1, 2026
NCT04383210 Active, not recruiting Phase 2 Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors September 29, 2020 March 2025
NCT01223248 Active, not recruiting Phase 3 Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy October 2010 October 2024
NCT03763838 Active, not recruiting N/A Acupressure for Fatigue in Ovarian Cancer Survivors October 7, 2019 June 18, 2024
NCT03732768 Active, not recruiting Phase 1 Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis June 8, 2020 August 2025
NCT01061619 Active, not recruiting Pathway to Diagnosis of Ovarian Cancer January 2010 November 2024
NCT02489006 Active, not recruiting Phase 2 A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer July 19, 2016 December 31, 2025
NCT01471483 Active, not recruiting Geriatric Assessment and Nursing Telephone Intervention in Elderly Women With Ovarian Cancer November 2011 November 2024
NCT04398446 Active, not recruiting Phase 2 Effect of Hemp-CBD on Patients With CIPN May 27, 2020 April 1, 2023
NCT04817449 Active, not recruiting Spectroscopy in Ovarian Cancer June 28, 2021 October 2024
NCT01706120 Active, not recruiting Phase 4 Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab October 2012 December 2024
NCT05059522 Active, not recruiting Phase 3 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing September 29, 2021 September 30, 2026
NCT05748353 Active, not recruiting Endocrine Disruptors and Life STILe in Breast Cancer Development January 1, 2012 July 15, 2024
NCT03029403 Active, not recruiting Phase 2 Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer February 12, 2018 February 12, 2025
NCT04780217 Active, not recruiting Phase 1/Phase 2 Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors August 10, 2021 August 2025
NCT04024254 Active, not recruiting Phase 2/Phase 3 A Study of Serum Folate Levels in Patients Treated With Olaparib July 21, 2020 December 31, 2024
NCT04145388 Active, not recruiting N/A Family History Study on Cancer Risk July 1, 2020 August 31, 2025
NCT01953159 Active, not recruiting Assessment of Paclitaxel-Induced Neuropathy August 29, 2013 December 2025
NCT04201561 Active, not recruiting Phase 3 High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy December 24, 2019 December 31, 2024
NCT05451849 Active, not recruiting Phase 1/Phase 2 A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer June 21, 2022 October 30, 2028
NCT03740165 Active, not recruiting Phase 3 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) December 18, 2018 May 29, 2026
NCT03079687 Approved for marketing Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
NCT04681248 Available Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
NCT05974410 Available Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
NCT04566393 Available Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
NCT02498665 Completed Phase 1 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies November 2015 September 2018
NCT03159572 Completed Homologous Recombination Inquiry Through Ovarian Malignancy Investigations March 28, 2017 February 16, 2022
NCT00006981 Completed Phase 1 Immunotoxin Therapy in Treating Patients With Advanced Cancer December 2000
NCT02897375 Completed Phase 1 Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors October 24, 2016 October 15, 2021
NCT01669798 Completed Phase 2 BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer February 2013 February 2018
NCT00006041 Completed Phase 1 Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer February 2000 February 2002
NCT00287885 Completed Phase 1 Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer March 2004 December 2008
NCT03652077 Completed Phase 1 A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies September 24, 2018 August 18, 2021
NCT00138242 Completed Phase 2 Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer December 2004 October 2006
NCT00088413 Completed Phase 1/Phase 2 PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer July 21, 2004 May 31, 2018
NCT00004604 Completed Phase 1 Biological Therapy in Treating Patients With Metastatic Cancer February 1997 July 2002
NCT00170664 Completed Phase 2 Taxol/ Carboplatin as First Line Therapy in Patients With Epithelial Ovarian Cancer January 1999 September 2004
NCT00058552 Completed Phase 2 A Study to Evaluate the Effect of HER2 Activation on rhuMAb 2C4 (Pertuzumab) in Subjects With Advanced Ovarian Cancer May 2003 July 2004
NCT00031954 Completed Phase 2 Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer August 2001
NCT02928549 Completed Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study September 22, 2016 August 26, 2019
NCT00407758 Completed Phase 2 Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer November 2006
NCT02631876 Completed Phase 3 A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer March 2, 2016 January 2020
NCT02537444 Completed Phase 2 Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191) November 2015 October 2018
NCT00628654 Completed Glycan Analysis in Diagnosing Cancer in Women With Ovarian Epithelial Cancer and in Healthy Female Participants October 2005 March 10, 2016
NCT03119285 Completed Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families April 2013 January 31, 2022
NCT00030108 Completed Phase 1 Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy November 2001 April 2010
NCT03367182 Completed Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer September 1, 2017 January 31, 2018
NCT04392102 Completed Phase 2 A Study of Niraparib in Patients With Relapsed Ovarian Cancer August 4, 2020 August 11, 2022
NCT01196559 Completed Phase 2 Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer January 2011 October 2014
NCT04430842 Completed Phase 1 Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S July 20, 2020 December 22, 2022
NCT00303940 Completed Phase 1 Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors December 2005 February 2010
NCT00478452 Completed Phase 1 Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients August 2005 August 2008
NCT00002538 Completed Phase 2 Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers September 1993
NCT02351479 Completed N/A Hula, a Physical Activity Intervention for Female-Cancer Survivors September 2013 December 2017
NCT00436644 Completed Phase 2 Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin March 2007 November 2012
NCT00002508 Completed Phase 1/Phase 2 Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors November 1990 September 2001
NCT00049556 Completed Phase 2 Gefitinib in Treating Patients With Cervical Cancer October 2002 August 2006
NCT02910622 Completed Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer. June 2012 June 2016
NCT01247779 Completed N/A Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy December 2010 November 2017
NCT01358071 Completed Phase 2 Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer June 2011 December 2016
NCT00470366 Completed Phase 2 Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors March 2007 June 2016
NCT02582931 Completed Phase 1 MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer December 2, 2015 December 13, 2018
NCT04068675 Completed N/A Effects of Centering Pre-operative Counseling on Patient Reported Anxiety February 24, 2020 June 30, 2021
NCT01469793 Completed Phase 1 A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer November 2011 December 2015
NCT02608684 Completed Phase 2 A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer February 8, 2016 March 7, 2022
NCT01544049 Completed Fallopian Tube Removal as a Method of Ovarian Cancer Prevention: A Descriptive Study December 2011 September 4, 2018
NCT00002901 Completed Phase 1 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function December 1996
NCT00403429 Completed Phase 2 MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer March 2006 July 2008
NCT00002600 Completed Phase 1 Combination Chemotherapy, Bone Marrow Transplantation, and Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer October 21, 1994 July 25, 2001
NCT00006235 Completed Phase 1 Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03940196 Completed Phase 3 Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3) March 22, 2019 May 18, 2023
NCT01538498 Completed Development for the Peritoneal Carcinomatosis Index (PCI) in Ovarian Cancer April 2008 February 2013
NCT00867503 Completed Phase 2 Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer February 2009 April 2013
NCT01691144 Completed Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project September 2012 December 2015
NCT00740116 Completed Phase 4 Tranexamic Acid in Surgery of Advanced Ovarian Cancer March 2008 June 2012
NCT00003449 Completed Phase 2 Combination Chemotherapy in Treating Patients With Platinum-Resistant Recurrent Ovarian Cancer May 1998 February 2004
NCT00757952 Completed Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction November 2007 December 2012
NCT03189108 Completed Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors May 22, 2017 May 18, 2023
NCT00325494 Completed Phase 1 A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer May 2006 September 2008
NCT00086892 Completed Phase 2 Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer June 2004
NCT00117442 Completed Phase 2 A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood August 2002 December 2004
NCT02121990 Completed Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer April 21, 2014 August 19, 2020
NCT03171506 Completed N/A Targeted Disruption to Cancer Metabolism and Growth Through Dietary Macronutrient Modification November 9, 2015 July 18, 2017
NCT02287519 Completed N/A Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention November 2014 December 2019
NCT03514121 Completed Early Phase 1 FPA150 in Patients With Advanced Solid Tumors March 27, 2018 May 10, 2021
NCT03804866 Completed Phase 2 NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018) March 2013 December 2016
NCT00230542 Completed Phase 2 Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer September 2005 April 2011
NCT00620295 Completed Phase 1 Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors March 2007 October 2009
NCT00967577 Completed Phase 1 177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors July 2009 December 31, 2021
NCT00170690 Completed Phase 3 Preference Study With Elderly Patients Recurrent Ovarian Cancer August 2004 April 2012
NCT02107066 Completed Phase 3 Women's Activity and Lifestyle Study in Connecticut May 2009 June 2013
NCT03452982 Completed Phase 2 Sentinel Lymph Node in Early Ovarian Cancer March 23, 2018 August 21, 2019
NCT00005026 Completed Phase 1 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer February 2000
NCT03023319 Completed Phase 1 Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors December 10, 2019 May 10, 2022
NCT01037751 Completed M. D. Anderson Symptom Inventory - Ovarian Cancer December 30, 2009 July 18, 2018
NCT00825201 Completed Phase 1 Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity January 2009 January 16, 2018
NCT04545632 Completed Docetaxel Ethanol-induced Symptoms; The Incidence and Risk Forecating Factor June 10, 2020 June 24, 2021
NCT00579007 Completed Decision-making Regarding Prophylactic Mastectomy and Oophorectomy in Women Seeking Genetic Counseling and Testing for BRCA1/2 Mutations March 11, 2003 November 20, 2019
NCT00709462 Completed Phase 1 A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01) March 2004 June 2010
NCT00003773 Completed Phase 1 IM-862 in Treating Patients With Recurrent Ovarian Cancer February 1999 August 2001
NCT00423852 Completed Phase 1/Phase 2 Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin August 2006 February 2013
NCT02092363 Completed Phase 1 Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer January 2014 December 2017
NCT00889382 Completed Phase 1/Phase 2 A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) August 5, 2009 August 25, 2014
NCT00002485 Completed Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer February 1992 September 2005
NCT00593580 Completed Phase 2 Bone Health in Gynecologic Cancers-does FOSAVANCE Help? February 2008 June 2011
NCT00043472 Completed Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk July 9, 2003
NCT00028912 Completed Phase 1 Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer November 2001
NCT00087087 Completed Phase 2 Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer July 2004
NCT00753545 Completed Phase 2 Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer August 28, 2008 October 12, 2023
NCT00020150 Completed Phase 1 Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors June 2000
NCT01778803 Completed Phase 1 Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer February 26, 2013 February 23, 2015
NCT01601548 Completed N/A Cancer and Mindfulness-Based Cancer Recovery After Chemotherapy July 2012 July 2013
NCT01253681 Completed Phase 1 Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer November 2010 January 2015
NCT01982500 Completed Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer March 2012 July 2017
NCT00545792 Completed Phase 2 Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers May 2007 October 2013
NCT00016224 Completed Phase 2 Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer January 2001 March 2004
NCT00338026 Completed Phase 1 A Phase I Study of ECO-4601 in Patients With Advanced Cancer February 2006 August 2007
NCT01689636 Completed Phase 1 Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients August 2000 July 2002
NCT01248273 Completed Phase 1 Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission November 2010 March 2017
NCT00003896 Completed Phase 2 S9912 Combination Chemo in Stage III Ovarian Cancer, September 1999 February 2008
NCT02764333 Completed Phase 2 TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer May 6, 2016 January 20, 2021
NCT00829959 Completed Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC) February 2009 August 2016
NCT00083928 Completed Phase 2 Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels May 2004 December 2006
NCT00765973 Completed Phase 1 Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors November 10, 2008 June 30, 2010
NCT00428610 Completed Phase 2 A Study of Chemotherapy Treatment for Patients With Ovarian Cancer February 2007 January 2012
NCT00531284 Completed Phase 1/Phase 2 Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma September 2007 May 22, 2017
NCT02530047 Completed Phase 1 Mesenchymal Stem Cells (MSC) for Ovarian Cancer May 16, 2016 June 13, 2019
NCT02262455 Completed Phase 1 Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors October 2014 January 13, 2017
NCT00002960 Completed Phase 1 SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) June 1999 July 2000
NCT05448586 Completed Opioid Free Anaesthesia in Oncologic Gynaecological Surgery: Is There Any Benefit? February 2, 2019 January 30, 2021
NCT03395080 Completed Phase 2 A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma March 5, 2018 January 27, 2021
NCT04580485 Completed Phase 1 INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors February 3, 2021 February 22, 2024
NCT01256268 Completed Phase 1 Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids June 13, 2011 August 3, 2017
NCT02531997 Completed N/A A Mind-body Intervention to Improve Body and/or Self Image August 2015 December 2017
NCT00022347 Completed Phase 2 TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer May 2001 December 2009
NCT01644825 Completed Phase 2 Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer December 2010 December 29, 2015
NCT01684878 Completed Phase 3 Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) October 22, 2012 April 28, 2016
NCT03635489 Completed Phase 3 A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer August 15, 2018 May 12, 2023
NCT00496106 Completed N/A Stress, Immunity and Cervical Cancer: Biobehavioral Outcomes August 2007 February 2011
NCT01167842 Completed Analysis of Tumors From Patients With Inherited Cancers Having Had Two Surgeries (Primary + Recurrent, or 2 Separate Types of Cancer) October 2009 January 14, 2022
NCT01734746 Completed N/A Sentinel Node Detection in Clinical Early Stage Ovarian Cancer October 2012 October 2014
NCT04630327 Completed Validation of the Russian and Kazakh Versions of the Beck Depression Inventory and Beck Anxiety Inventory January 13, 2020 May 1, 2022
NCT00345709 Completed Elizabeth Registry for Low Grade Ovarian Cancer September 2003 October 2014
NCT00002559 Completed Phase 1/Phase 2 Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin January 1994 January 2003
NCT00004082 Completed Phase 1 Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors July 1999 December 2010
NCT00061308 Completed Phase 2 Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer December 2002
NCT04669002 Completed Phase 2 EP0057 in Combination With Olaparib in Advanced Ovarian Cancer December 14, 2020 May 5, 2023
NCT00578006 Completed N/A Internet-based System for Cancer Patients to Self-report Toxicity March 2004 January 2017
NCT00003072 Completed Phase 2 Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer May 1997 October 1998
NCT00817479 Completed Phase 4 Tumor Gene Expression in Women With Ovarian Cancer January 2003 January 2013
NCT01975831 Completed Phase 1 A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab December 19, 2013 July 2, 2021
NCT00617773 Completed Phase 2 Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer May 2008 June 2012
NCT02855697 Completed Early Phase 1 Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer May 26, 2017 December 31, 2021
NCT00005051 Completed Phase 2 Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer August 1999
NCT00461786 Completed Phase 2 A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer September 2004 May 2008
NCT00005956 Completed N/A Biological Therapy in Treating Patients With Advanced Cancer February 2000 July 2002
NCT02372864 Completed N/A Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy February 2015 December 2016
NCT00017017 Completed Phase 1/Phase 2 CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer February 2001 December 2009
NCT01686256 Completed Phase 1 Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer August 2001
NCT00059618 Completed Phase 1 PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer April 2003 April 2007
NCT00005590 Completed Phase 3 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma August 1999 September 2005
NCT03558139 Completed Phase 1 Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy May 23, 2018 December 3, 2020
NCT00002474 Completed Phase 2 Combination Chemotherapy and Bone Marrow Transplant in Treating Patients With Refractory or Recurrent Ovarian Cancer February 1991 October 2005
NCT00003107 Completed Phase 1 Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors October 1997
NCT00866697 Completed Phase 3 Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer May 26, 2009 August 24, 2017
NCT00610714 Completed Phase 2 AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer April 2008 January 2012
NCT02312167 Completed N/A Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE) October 2014 October 2015
NCT01185626 Completed N/A ROGYcare: The Impact of a Cancer Survivorship Care Plan on Patient Reported Outcomes and Health Care Providers April 2011 July 2016
NCT00945139 Completed Phase 2 Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) March 2007 August 2011
NCT00937560 Completed Phase 2 A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer June 25, 2009 July 1, 2013
NCT04881045 Completed Phase 1 Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. August 18, 2021 October 24, 2023
NCT01690598 Completed Phase 1/Phase 2 Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status November 2012 February 2015
NCT00114166 Completed Phase 2 Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer January 2005
NCT01219777 Completed Phase 1 Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian September 2010 May 2015
NCT01346761 Completed N/A Risk Education and Assessment for Cancer Heredity August 2009 December 2012
NCT03863912 Completed N/A Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients December 1, 2017 November 29, 2018
NCT00746018 Completed N/A Thermal Spread Into the Interstitial Portion of the Fallopian Tubes Using the Ligasure Device at Time of Hysterectomy August 2008 July 2017
NCT02383251 Completed Phase 2 Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer June 15, 2015 December 31, 2020
NCT00028743 Completed Phase 3 Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer August 31, 2001 January 10, 2013
NCT00662233 Completed Early Phase 1 Combination Chemotherapy in Treating Patients With Sarcoma October 1991 October 21, 2013
NCT00383279 Completed N/A Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer February 2006 February 2007
NCT00432094 Completed Phase 2 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors December 19, 2006 March 2021
NCT01588522 Completed Phase 1 Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease July 2012 March 2017
NCT01580696 Completed Phase 1/Phase 2 Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer April 2012 July 31, 2016
NCT00003269 Completed Phase 2 Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors February 1998 January 2001
NCT02133703 Completed N/A Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility October 2015 July 1, 2022
NCT00003002 Completed Phase 1 HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer April 1996 January 2004
NCT04352439 Completed Phase 4 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy August 8, 2020 March 2, 2022
NCT00039585 Completed Phase 2 Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor May 2002
NCT01379989 Completed Phase 3 INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer June 2011 December 17, 2020
NCT04237090 Completed Phase 3 Feasibility of a Clinical Trial Comparing the Use of Cetirizine to Replace Diphenhydramine in the Prevention of Reactions Related to Paclitaxel February 14, 2020 September 4, 2020
NCT03662204 Completed Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors August 23, 2018 March 31, 2022
NCT00672295 Completed Phase 1 PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer August 2007 November 2012
NCT02725489 Completed Phase 2 Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers June 3, 2016 December 2, 2020
NCT03921658 Completed The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer October 22, 2019 April 2, 2024
NCT00368420 Completed Validation of a Score of Predictive Factors for Complete Resection in Platinum-sensitive Recurrent Ovarian Cancer September 2006 October 2009
NCT00228319 Completed Phase 1/Phase 2 Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants October 2002 August 2007
NCT02118285 Completed Phase 1 Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer July 28, 2014 November 12, 2015
NCT00686465 Completed N/A Positron Emission Tomography/Computed Tomography (PET/CT) for the Diagnosis of Recurrent Cancer: a Feasibility Study March 2009 July 2012
NCT01610869 Completed Phase 2 Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer August 2014 January 11, 2018
NCT04507191 Completed PDL1 in Ovarian High Grade Serous Carcinoma December 1, 2012 December 30, 2019
NCT00525460 Completed Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function April 2006 December 2014
NCT01132014 Completed Early Phase 1 Autologous OC-DC Vaccine in Ovarian Cancer May 2010 May 30, 2018
NCT02580058 Completed Phase 3 A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) December 21, 2015 July 12, 2022
NCT03704467 Completed Phase 1 Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer March 4, 2019 November 6, 2019
NCT00770536 Completed Phase 1 AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR January 2009 June 2015
NCT04898842 Completed N/A Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet March 2, 2021 November 2, 2022
NCT00033488 Completed N/A Screening Women at High Genetic Risk for Ovarian Cancer September 2000 March 2010
NCT01204749 Completed Phase 3 TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer November 2010 December 2016
NCT00004909 Completed Effect of Chemotherapy Given Either by Mouth or by Infusion on the Quality of Life of Patients With Recurrent Ovarian Epithelial Cancer November 1999 November 2002
NCT03004391 Completed Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125 April 1, 2017 December 31, 2022
NCT00768144 Completed Phase 2 Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma September 2008 February 2013
NCT00002568 Completed Phase 3 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer June 1994
NCT00078845 Completed Phase 2 Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors May 2004 May 2007
NCT00170677 Completed Phase 2 Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer September 2005 January 2013
NCT00900094 Completed UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer June 2000 October 2007
NCT06379191 Completed N/A The Efficacy of WeChat-based Multidisciplinary Full-course Nutritional Management Program February 1, 2023 October 30, 2023
NCT04284852 Completed Phase 2 Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting May 1, 2020 October 1, 2023
NCT03931304 Completed Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2) February 1, 2018 September 30, 2018
NCT00003385 Completed Phase 1 Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer March 1999
NCT00652691 Completed Phase 1 Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer August 1998 May 4, 2016
NCT02001272 Completed Phase 2 EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer December 2013 February 2020
NCT00312988 Completed Phase 3 Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy January 2000 December 2009
NCT03164980 Completed Phase 4 Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer November 27, 2017 August 8, 2023
NCT03082976 Completed Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region July 16, 2017 July 24, 2019
NCT02393898 Completed BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older April 23, 2015 June 14, 2019
NCT00007813 Completed Phase 1 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors May 31, 1997 February 1, 2005
NCT01610206 Completed Phase 2 A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer September 2012 December 31, 2020
NCT01432015 Completed Phase 4 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting September 2011 March 2015
NCT00014456 Completed Phase 1 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors March 2000 October 2005
NCT01440504 Completed Ex Vivo Evaluation of the Interest of the Association of Platinum With a Molecule BH3-mimetic ABT-737 in Samples of Ovarian Tumors April 2010 January 2013
NCT01591772 Completed Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer April 24, 2012 May 25, 2022
NCT00268918 Completed Phase 1 Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients September 2005 January 2011
NCT03509636 Completed Phase 1 A Study of Fluzoparib(SHR-3162)in BRCA1/2-mutant Relapsed Ovarian Cancer April 4, 2018 July 23, 2020
NCT04803305 Completed Phase 1 Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia May 11, 2021 August 9, 2022
NCT01482715 Completed Phase 1/Phase 2 A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) November 2011 May 2019
NCT00263822 Completed Phase 3 Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer September 2005
NCT00070096 Completed Phase 2 Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors August 2003 June 2007
NCT05476341 Completed Phase 1 A Phase I Clinical Trial of Bevacizumab Injection April 6, 2017 August 18, 2017
NCT00345540 Completed Phase 2 Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer July 2006 June 2008
NCT00217568 Completed Phase 2 Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer May 2005
NCT03329950 Completed Phase 1 A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies December 1, 2017 September 13, 2022
NCT00179712 Completed Phase 1/Phase 2 Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma April 2005 November 2006
NCT00040911 Completed N/A Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma April 2005 January 2011
NCT00070967 Completed Phase 2 Acupuncture to Improve Quality of Life in Patients With Advanced Cancer September 2001 February 2005
NCT00239980 Completed Phase 2 Fragmin in Ovarian Cancer: Utility on Survival (FOCUS) October 2005 January 2010
NCT00034151 Completed Phase 2 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer March 2002 September 2007
NCT01357161 Completed Phase 2 A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) July 26, 2011 August 8, 2016
NCT00870233 Completed Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life March 24, 2009 February 12, 2018
NCT01246440 Completed Phase 2 Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission June 2010 December 2014
NCT03414047 Completed Phase 2 A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer April 10, 2018 October 3, 2020
NCT01113957 Completed Phase 2 A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer March 2010 June 2013
NCT03471572 Completed Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India March 22, 2018 December 21, 2018
NCT01223235 Completed N/A Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab October 2010 September 2017
NCT00002734 Completed Phase 1 Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer March 1996
NCT00001944 Completed Phase 1 Vinorelbine and XR9576 to Treat Cancer December 1999 June 2001
NCT00465725 Completed Phase 1 A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors April 2007 July 2009
NCT00806156 Completed Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer October 2008 January 2013
NCT01372553 Completed Guilford Genomic Medicine Initiative (GGMI) October 2009 April 2012
NCT00004012 Completed Phase 2 Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer December 1998 December 2000
NCT00959582 Completed Phase 1 Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) September 2009 October 2011
NCT00012090 Completed Phase 2 Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum September 2000 April 2004
NCT01402271 Completed Phase 1/Phase 2 Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer July 2012 July 13, 2020
NCT02298855 Completed N/A Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer. January 2006 May 2010
NCT00382811 Completed Phase 3 OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovarian Cancer October 2006 April 2011
NCT01091259 Completed Phase 2 Irinotecan and Bevacizumab for Recurrent Ovarian Cancer March 2010 May 2015
NCT00003778 Completed Phase 2 Dolastatin 10 in Treating Patients With Recurrent or Metastatic Soft Tissue Sarcoma April 1999
NCT00459290 Completed Phase 2 Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer May 2007 July 2010
NCT00550784 Completed Phase 1 Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer January 2001 October 2014
NCT00744718 Completed Phase 2 Bevacizumab and Carboplatin for Patients With Ovarian Cancer August 2008 December 2015
NCT00587093 Completed N/A A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer July 2001 February 16, 2018
NCT00098878 Completed Phase 3 Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer March 2004 July 2010
NCT01432145 Completed Phase 2 A Clinical Trial in Patients With Breast Cancer Susceptibility Gene (BRCA) Defective Tumours May 2011 May 2015
NCT01242436 Completed N/A Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis January 2011 December 2014
NCT03454451 Completed Phase 1 CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers April 25, 2018 February 19, 2023
NCT03127098 Completed Phase 1/Phase 2 QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer June 26, 2017 December 7, 2017
NCT03689192 Completed Phase 1 Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors December 17, 2018 January 19, 2022
NCT02622776 Completed N/A Advanced Methods for Cancer Detection by Vaginal Screening February 2016 December 2018
NCT00483782 Completed Phase 3 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer April 2006
NCT03980028 Completed Role of Surgery in Advanced Ovarian Cancer January 1, 2018 June 1, 2019
NCT00250094 Completed Phase 1 Clinical Benefit of Topoisomerase Downregulation May 2004 March 2006
NCT01826227 Completed N/A Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer March 2013 December 2016
NCT00097409 Completed Phase 2 Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer December 2004 May 2007
NCT02015416 Completed Phase 1 A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer November 2013 March 2017
NCT04154163 Completed Appropriate Dosing to Optimise Personalised Cancer Treatments January 10, 2020 March 5, 2021
NCT00346385 Completed Phase 1 BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors March 2002 October 2011
NCT01953107 Completed Phase 4 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. November 2013 December 2020
NCT00702299 Completed Phase 1 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer September 2007 October 2012
NCT02009631 Completed Phase 1 A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors November 2013 December 2014
NCT01306032 Completed Phase 2 Phase II ABT-888 With Cyclophosphamide January 12, 2011 December 15, 2016
NCT00090610 Completed Phase 2 Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer October 2003 October 2009
NCT00002903 Completed Phase 2 Docetaxel in Treating Patients With Recurrent or Refractory Germ Cell Cancer July 1995
NCT04785716 Completed Real-life Use of Niraparib in a Patient Access Program in Norway July 31, 2017 August 3, 2020
NCT02440425 Completed Phase 2 Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer October 20, 2015 May 27, 2021
NCT01618136 Completed Phase 1/Phase 2 An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors January 2012 July 2015
NCT02865811 Completed Phase 2 Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer September 15, 2016 March 2022
NCT01704651 Completed Phase 3 Accelerating Gastrointestinal Recovery January 2013 October 2015
NCT00006230 Completed Phase 2 Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer May 2000
NCT00722592 Completed Phase 2 Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) September 2008 December 2012
NCT02431559 Completed Phase 1/Phase 2 Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer December 2, 2015 June 10, 2021
NCT00856791 Completed Phase 2 Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients March 2009 July 2011
NCT00005049 Completed Phase 2 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer May 1997
NCT00343044 Completed Phase 2 Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers June 2006 August 2011
NCT00667641 Completed Phase 1 Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors March 2007 February 2009
NCT00664781 Completed Phase 2 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer December 2007 January 2015
NCT03629756 Completed Phase 1 A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies July 24, 2018 September 3, 2021
NCT00003569 Completed Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel March 1998
NCT00109993 Completed Phase 2 Campath-1H + FK506 and Methylprednisolone for GVHD January 2005 May 2007
NCT05258747 Completed Phase 1 A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer April 7, 2022 October 20, 2022
NCT02340611 Completed Phase 2 A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib June 2015 June 2018
NCT01831089 Completed Phase 1 Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors September 2013 July 2016
NCT01954355 Completed Phase 1 LDE225 and Paclitaxel in Solid Tumors September 2013 November 2016
NCT00002489 Completed Phase 2 Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors October 1991 June 2002
NCT00877253 Completed Phase 1 Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer May 2008 June 2009
NCT01068483 Completed Phase 1 Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients November 2008 August 2012
NCT00420381 Completed Phase 2 Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer January 2007 December 2014
NCT00479817 Completed Phase 2 Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer July 5, 2007 December 9, 2019
NCT00043082 Completed Phase 3 S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer August 2002 July 2011
NCT00003657 Completed Phase 2 High-dose ICE With Amifostine July 1998 June 2002
NCT00335491 Completed N/A Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer Survivors March 2006 March 2010
NCT04334239 Completed Effectiveness of Care in Certified Cancer Centres in Germany May 1, 2017 August 31, 2021
NCT02856841 Completed The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer January 2015 June 2016
NCT00526617 Completed Phase 1 A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients August 2007
NCT04630769 Completed Phase 1 FT516 and IL2 With Enoblituzumab for Ovarian Cancer April 2, 2021 January 1, 2022
NCT01521325 Completed Phase 1 A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers September 2011 March 2013
NCT01040312 Completed An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors October 15, 2009 September 2, 2015
NCT00096993 Completed Phase 2 A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer January 2005 September 2007
NCT00711932 Completed The Effect of TRA-8 on Ovarian Cancer Tissue August 2008 January 2013
NCT00032162 Completed Phase 1/Phase 2 Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer August 2001
NCT00004060 Completed Phase 2 Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer July 1999 September 2000
NCT00006043 Completed Phase 2 Temozolomide in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to Cisplatin February 2000 November 2001
NCT02916875 Completed Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making October 2016 January 2022
NCT00426257 Completed Phase 3 Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer February 2007 August 16, 2017
NCT02867956 Completed Phase 2 Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer August 10, 2016 September 10, 2019
NCT00165152 Completed N/A Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing July 1998 June 2005
NCT00321932 Completed Phase 2 Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant July 2005 March 2012
NCT00569673 Completed Phase 2 Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer March 2008
NCT00436410 Completed Early Phase 1 Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer December 2006 August 2009
NCT05490407 Completed N/A Role of the ATP7A Transporter in Ovarian Cancer March 17, 2021 January 1, 2024
NCT01416038 Completed Phase 1 Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer December 2011 May 2013
NCT03073525 Completed Phase 2 A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers May 31, 2017 May 18, 2022
NCT02714621 Completed N/A MR-HIFU for Recurrent Gynaecological Cancer May 2016 March 31, 2020
NCT00004157 Completed Phase 2 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors August 2000 April 2002
NCT03989336 Completed Phase 2 An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer December 23, 2020 December 10, 2023
NCT03042702 Completed Phase 2 A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer February 9, 2017 November 10, 2017
NCT01042847 Completed How Our Immune System Can Help Fight Cancer January 2010 February 2015
NCT02069769 Completed N/A Ensuring Communication in Hospice by Oncology Study (ECHO) January 2014 January 2017
NCT00025441 Completed Phase 2 Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors November 1998 March 2010
NCT02305498 Completed N/A Yoga Practice for Breast or Ovarian Cancer Patients November 24, 2014 March 11, 2019
NCT00582322 Completed Genetic Studies in Breast Cancer February 1992 July 2009
NCT03505307 Completed Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) May 21, 2018 December 7, 2020
NCT03180307 Completed Phase 3 OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer January 26, 2018 October 16, 2020
NCT03783949 Completed Phase 2 European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer November 30, 2018 September 1, 2023
NCT00004934 Completed Phase 3 Paclitaxel and Carboplatin With or Without Epirubicin in Treating Patients With Stage IIB, Stage III, or Stage IV Invasive Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer August 1999 May 2003
NCT00014690 Completed Phase 2 ZD9331 With or Without Topotecan in Treating Patients With Refractory or Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer March 2001 February 2004
NCT00072267 Completed Phase 2 UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer January 2004
NCT01309230 Completed Phase 2 A Trial of FANG™ Vaccine for Participants With Ovarian Cancer March 8, 2011 February 2, 2022
NCT00245050 Completed Phase 3 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer April 2004 September 2011
NCT04440943 Completed Phase 1 A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies August 4, 2020 April 6, 2023
NCT05372692 Completed N/A Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer April 12, 2022 February 1, 2023
NCT00008138 Completed Phase 2 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer March 2001 November 2009
NCT02593422 Completed N/A Writing About Experiences With Ovarian Cancer April 2015 December 2016
NCT01065662 Completed Phase 1 AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies February 2010 March 2021
NCT02222883 Completed Prevalence of BRCA in Patients With Ovarian Cancer March 2015 April 1, 2021
NCT02681237 Completed N/A A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer April 29, 2016 March 25, 2022
NCT01096394 Completed Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer November 2009 October 2015
NCT01739218 Completed Phase 2 A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable February 1, 2013 August 17, 2016
NCT00846612 Completed Phase 1 Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer January 2008 June 2012
NCT02517554 Completed A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services August 2015 November 2019
NCT00058032 Completed N/A CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women April 17, 2001 June 30, 2020
NCT00004876 Completed Phase 2 Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer August 1999
NCT01863693 Completed An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1) May 10, 2013 June 15, 2018
NCT05204342 Completed Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France January 1, 2012 December 30, 2021
NCT00003345 Completed Phase 2 Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer October 1997 October 2001
NCT00003334 Completed Phase 2 Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract March 1997
NCT00091273 Completed Phase 1 Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer June 2004 June 2007
NCT00508378 Completed Chemotherapy-Related Toxicities In Ovarian Cancer Patients January 2001 November 3, 2020
NCT01623349 Completed Phase 1 Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer September 2012 December 2020
NCT00063401 Completed Phase 2 Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer September 2003 June 2006
NCT00569257 Completed Phase 2 Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors December 2007 July 2011
NCT00002558 Completed Phase 1/Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors January 1994 April 2009
NCT02984423 Completed FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study December 27, 2016 June 30, 2019
NCT00006454 Completed Phase 3 Paclitaxel Plus Carboplatin With or Without Topotecan in Treating Patients With Stage IIB, Stage III, or Stage IV Ovarian Epithelial Cancer December 1999 August 2006
NCT00856180 Completed Phase 2 Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies February 2009 January 2014
NCT00313599 Completed Phase 1 Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors February 2006 December 2013
NCT01834469 Completed Phase 1/Phase 2 Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients March 2013 October 2014
NCT00296816 Completed Phase 2 TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary March 2006 August 2011
NCT00002977 Completed Phase 1 Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission January 1997
NCT00986206 Completed Lysophosphatidic Acid Assay in Patients With Ovarian Cancer or Who Are at Risk for Ovarian Cancer June 2009 July 2015
NCT02960594 Completed Phase 1 hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse December 2014 November 9, 2018
NCT00189566 Completed Phase 2 Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse April 2004 April 2009
NCT01968213 Completed Phase 3 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) April 7, 2014 July 7, 2022
NCT00526149 Completed Phase 2 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors July 2007
NCT02178722 Completed Phase 1/Phase 2 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers July 17, 2014 November 6, 2020
NCT02326064 Completed Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4 May 2015 June 2016
NCT00900523 Completed Prostaglandin Metabolite in Urine Samples From Patients With Ovarian Cancer November 2006 July 2008
NCT02418624 Completed Phase 1 Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer May 2015 January 2019
NCT00837993 Completed Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System August 2007 December 2012
NCT00191334 Completed Phase 2 Gemcitabine in Ovarian Cancer December 2004 December 2007
NCT00315692 Completed Risk of Ovarian Cancer in Patients With a Pelvic Mass December 2005 February 2007
NCT00019552 Completed Phase 2 Irofulven in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer September 1998 April 2004
NCT00003588 Completed Phase 1 Gene Therapy in Treating Patients With Ovarian Cancer September 1998
NCT00019136 Completed Phase 1 Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer February 1997
NCT01170299 Completed N/A Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer October 2009 January 2014
NCT01583322 Completed Phase 2 Vargatef in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Ovarian Cancer June 2012 March 2016
NCT00010179 Completed Phase 2 Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer October 31, 2000 September 22, 2008
NCT02399592 Completed Phase 2 Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer March 2015 July 2019
NCT00231075 Completed Phase 2 Evaluation of the Safety and Efficacy of Paraplatin in Combination With Taxol in Patients of 70 Years and Older With Ovary Cancer F.I.G.O. Stages III-IV January 2001 May 2007
NCT00036959 Completed Phase 1 ABT-751 in Treating Young Patients With Refractory Solid Tumors March 2002 February 2010
NCT01670799 Completed Early Phase 1 Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer March 2012 December 2015
NCT00267696 Completed Phase 2 Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer November 2005 December 2013
NCT00003214 Completed Phase 3 Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer July 1996 April 2000
NCT03394885 Completed Phase 1/Phase 2 Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer June 19, 2018 July 20, 2020
NCT00004008 Completed Phase 2 Bryostatin 1 in Treating Patients With Ovarian Epithelial Cancer July 1999 May 2003
NCT00003763 Completed N/A Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer December 8, 1997 May 3, 2000
NCT00002526 Completed Phase 2 Chemotherapy in Treating Patients With Advanced Sarcoma January 1993 September 1995
NCT03205176 Completed Phase 1 AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas June 30, 2017 April 8, 2021
NCT00776958 Completed Lynne Cohen Consortium Project: Multi-Center Database/Registry July 2008
NCT03507543 Completed Phase 1 The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors February 3, 2017 March 17, 2021
NCT01196741 Completed Phase 2/Phase 3 Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer March 2011 January 2014
NCT00003998 Completed Phase 3 Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer October 1998 December 2004
NCT02529150 Completed N/A WISER After Ovarian Cancer - Exercise Pilot Study May 2015 May 6, 2016
NCT02914470 Completed Phase 1 Carboplatin-cyclophosphamide Combined With Atezolizumab January 2017 October 2021
NCT01824615 Completed Phase 2 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma January 2013 January 2016
NCT01445418 Completed Phase 1 AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer May 12, 2008 October 18, 2019
NCT00692900 Completed Phase 1 Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer December 2008 October 2013
NCT00004066 Completed Phase 2 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma June 1999 October 2003
NCT00103545 Completed Phase 1/Phase 2 Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response July 2003 August 2004
NCT01905163 Completed Phase 2 Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients August 2013 July 2017
NCT04417192 Completed Phase 2 Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer December 1, 2020 June 30, 2023
NCT00003103 Completed Phase 1/Phase 2 Chemotherapy in Treating Patients With Solid Tumors August 1997 August 2002
NCT00444054 Completed N/A The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer February 2006 May 2012
NCT00959647 Completed Phase 2 A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study September 2009 January 2014
NCT00091377 Completed Phase 1/Phase 2 Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer August 2004 March 2008
NCT00410657 Completed Phase 2 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant July 2006
NCT00782145 Completed Phase 3 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families June 2008 June 2011
NCT05529303 Completed N/A Prolonged Grief and Perception of Femininity in Gynecological Cancer Patients February 26, 2023 September 18, 2023
NCT00946140 Completed Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study July 2009 October 2013
NCT00826150 Completed Phase 1/Phase 2 Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer June 2009 February 2012
NCT00004895 Completed Phase 2 Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery October 1999 October 2002
NCT00002928 Completed Phase 2 Paclitaxel in Treating Patients With Recurrent or Progressive Advanced Ovarian Cancer January 1997 August 2001
NCT00237627 Completed Phase 1/Phase 2 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer May 2001 January 2010
NCT02465892 Completed N/A Pillars4Life Trial May 2015 October 2016
NCT03759600 Completed Phase 2 Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer December 26, 2018 December 28, 2022
NCT00066729 Completed Phase 1 Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer June 23, 2003 August 1, 2013
NCT02374827 Completed N/A Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE) April 2015 September 2017
NCT00390611 Completed Phase 2 Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer October 2006 April 2014
NCT00004083 Completed Phase 2 Liposomal Cisplatin in Treating Patients With Recurrent Ovarian Cancer February 1999
NCT00003939 Completed Phase 2 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma
NCT00604994 Completed Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer June 2008 April 2013
NCT00684801 Completed Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers August 2007 December 2011
NCT00400348 Completed Phase 2 Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer October 2006 November 2008
NCT01172028 Completed Phase 1 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors September 2005 July 2014
NCT02237690 Completed Phase 1 Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer September 2014 August 2016
NCT04626895 Completed N/A Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers June 4, 2019 October 1, 2020
NCT00004921 Completed Phase 3 High-Dose Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer That Has Been Removed During Surgery September 1998 September 2007
NCT00471432 Completed Phase 1 OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors April 4, 2003 December 21, 2009
NCT00003136 Completed Phase 1/Phase 2 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer December 1996 October 2001
NCT05300828 Completed Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer October 19, 2015 December 31, 2022
NCT04676334 Completed Phase 3 CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib March 22, 2021 March 8, 2023
NCT00003080 Completed Phase 1 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Persistent or Platinum Refractory Stage III or IV Ovarian Cancer September 1996 May 2001
NCT03367260 Completed The Treatment Preferences of Women Diagnosed With Ovarian Cancer October 19, 2017 January 4, 2019
NCT00005046 Completed Phase 1 Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer April 2000
NCT00562640 Completed Phase 1 Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009) October 16, 2007 August 3, 2021
NCT00003887 Completed Phase 2 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation August 1998 February 2003
NCT00879840 Completed Assessment of Screening Modalities for Gynecologic Cancers April 9, 2009 November 16, 2020
NCT00006028 Completed Phase 2 Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy January 2001
NCT01567891 Completed Phase 1/Phase 2 CT Antigen TCR-redirected T Cells for Ovarian Cancer. July 9, 2013 June 6, 2017
NCT00097019 Completed Phase 2 A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed February 2005 May 2006
NCT01163552 Completed Phase 2 Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity June 2010 May 2014
NCT03038100 Completed Phase 3 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer March 8, 2017 August 12, 2022
NCT00453310 Completed Phase 2 Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment March 2007 November 2008
NCT03266185 Completed N/A Shorter Scalp Cooling Time in Paclitaxel December 20, 2017 August 28, 2020
NCT00003322 Completed Phase 3 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer March 1998
NCT03639246 Completed Phase 1 Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer December 6, 2018 December 30, 2022
NCT00003173 Completed Phase 2 High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors September 1997 May 2003
NCT00064311 Completed Phase 1/Phase 2 Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation June 2003 September 2004
NCT00033605 Completed Phase 3 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis April 2002 July 2006
NCT02759588 Completed Phase 1/Phase 2 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer May 2016 December 31, 2022
NCT00831636 Completed Phase 1/Phase 2 A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer April 2008 April 2010
NCT00993655 Completed Phase 2 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer March 3, 2010 July 11, 2016
NCT00315861 Completed Phase 1 Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies March 2006 January 2009
NCT01505829 Completed Diffusion-weighted Imaging Study in Cancer of the Ovary August 2012 October 13, 2018
NCT00005952 Completed Phase 1/Phase 2 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors August 2000 November 2005
NCT03837327 Completed Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy April 16, 2019 January 22, 2024
NCT02792959 Completed N/A Evaluation of Response to the Neoadjuvant Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging August 2014 August 2017
NCT02033551 Completed Phase 1 A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors December 2013 September 2016
NCT00408590 Completed Phase 1 Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer April 19, 2004 November 7, 2017
NCT00003892 Completed Phase 2 ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer February 1, 1999 September 22, 2008
NCT03508011 Completed Phase 1 A Study of IMP4297 in Patients With Advanced Solid Tumors August 23, 2017 December 16, 2020
NCT03551171 Completed Phase 1 The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer December 19, 2017 July 10, 2018
NCT00574678 Completed Phase 1/Phase 2 Analyzing the Composition of Tears to Identify Cancer December 2006 February 2016
NCT00284427 Completed Phase 2 Safety of Antioxidants During GYN Cancer Care September 2005 December 2006
NCT01065441 Completed Phase 1/Phase 2 Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer December 2010 July 2013
NCT00655447 Completed Examining the Long-Term Risks of Oophorectomy January 1980 June 2004
NCT04330716 Completed N/A Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers December 1, 2020 December 31, 2023
NCT01041235 Completed Phase 1 Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies December 2009 December 2011
NCT02354586 Completed Phase 2 A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens March 23, 2015 August 23, 2021
NCT01262040 Completed N/A Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive December 14, 2010 October 29, 2018
NCT03779399 Completed Treg, Th17 Cells, NKT in Epithelial Ovarian Tumor December 1, 2011 December 31, 2016
NCT01216813 Completed Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer August 2010 December 2010
NCT02785887 Completed N/A Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients August 1, 2014 September 25, 2018
NCT00102375 Completed Phase 3 Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer December 1999 October 2004
NCT00381173 Completed Phase 1 A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing November 2006 October 2008
NCT00189345 Completed Phase 2 Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients May 2004 October 2005
NCT04284631 Completed Prognostic Value of Her2neu and EGFR in Primary Ovarian High Grade Serous Carcinoma. January 1, 2012 December 30, 2019
NCT00052468 Completed Phase 3 Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer August 2002 January 2011
NCT00021034 Completed Phase 1 Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer March 2001 August 2001
NCT00610740 Completed Phase 2 CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer July 2006 April 2008
NCT00157560 Completed Phase 2 Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma December 2000 July 2005
NCT00317772 Completed Phase 1/Phase 2 Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer September 2, 2004 November 4, 2020
NCT02766582 Completed Phase 2 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer October 2016 December 30, 2023
NCT00066651 Completed Phase 1 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors July 2003
NCT04461457 Completed Early Phase 1 Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2 February 5, 2005 January 19, 2012
NCT01422265 Completed Patient Reported Symptoms in Ovarian Cancer (PRECISION) June 2011 April 2015
NCT00002764 Completed Phase 3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma April 1996
NCT01997190 Completed Phase 1 Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion October 2013 February 2018
NCT03470402 Completed N/A Decision Support for BRCA Testing in Ethnically Diverse Women December 13, 2017 August 17, 2020
NCT03881683 Completed N/A Determination of the Feasibility of Tumoural Somatic Mutations Detection in Blood of Patients With Ovarian Cancer February 21, 2020 February 19, 2021
NCT01696032 Completed Phase 2 SGI-110 in Combination With Carboplatin in Ovarian Cancer September 2012 August 2016
NCT00001383 Completed Phase 1 A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 March 1994 January 2001
NCT03219268 Completed Phase 1 A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms August 18, 2017 February 8, 2023
NCT00019019 Completed Phase 1 Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas October 1994 July 2006
NCT02973750 Completed Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer October 20, 2016 July 18, 2020
NCT00804258 Completed Palliative Care During Intraperitoneal Chemotherapy in Patients With Ovarian Cancer August 2007 January 2012
NCT03345485 Completed Phase 1/Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors October 6, 2017 March 29, 2023
NCT06145295 Completed N/A The Effectiveness of an Online Support Group in Enhancing Recovery Identity and Health-Related Quality of Life June 1, 2023 November 1, 2023
NCT00316173 Completed Phase 2 Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer March 2005 March 2009
NCT04927013 Completed N/A Connecting Families to Overcome Ovarian Cancer July 24, 2021 February 21, 2023
NCT00563836 Completed Phase 2 Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer November 2007 August 2010
NCT02179515 Completed Phase 1 Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) June 28, 2014 February 28, 2018
NCT04298827 Completed N/A Gyn Onc Prehab Study July 21, 2020 March 1, 2024
NCT00003358 Completed Phase 1 Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer January 1998
NCT03742713 Completed Phase 2 Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer October 1, 2018 December 1, 2020
NCT03538028 Completed Phase 1 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies June 18, 2018 October 7, 2020
NCT01705158 Completed Phase 1/Phase 2 Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum October 2012 April 2017
NCT00005858 Completed Phase 1 LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer April 2000 December 2003
NCT00003518 Completed Phase 2 Paclitaxel Plus Gemcitabine in Treating Patients With Refractory Metastatic Germ Cell Tumors January 25, 1999
NCT02567253 Completed Phase 2 Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer March 2016 August 25, 2021
NCT00421889 Completed Phase 1/Phase 2 A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment August 2005 February 2009
NCT00003811 Completed Phase 2 Combination Chemotherapy Plus Amifostine in Treating Children With Malignant Germ Cell Tumors April 2000 September 2007
NCT01459653 Completed Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor March 2010 August 2013
NCT04817501 Completed Phenotypic Spectrum of CTCs in Tumors of the Female Reproductive System February 14, 2014 December 1, 2022
NCT00023699 Completed Phase 2 Gefitinib in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer August 2001 May 2006
NCT00003772 Completed Quality-of-Life Assessment in Patients With Ovarian Cancer January 1999 February 2003
NCT00295945 Completed Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer March 2005 December 2009
NCT02560337 Completed Phase 2 Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy. September 2015 June 1, 2019
NCT00002671 Completed Phase 2 Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer December 1995
NCT01012336 Completed Phase 2 Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin May 2010 April 2012
NCT00112957 Completed Phase 2 Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer December 2004 May 2009
NCT01104675 Completed Phase 2 Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer April 2010 December 2012
NCT06385912 Completed Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian Cancer July 1, 2006 February 10, 2021
NCT02877862 Completed N/A Mobile Phone Technology to Increase Genetic Counseling February 2016 February 2018
NCT00158379 Completed Phase 2 Taxol Carboplatin and Erythropoetin July 2003 June 2008
NCT03840200 Completed Phase 1 A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. June 12, 2019 January 4, 2022
NCT00620243 Completed Early Phase 1 Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer. June 2004 November 2008
NCT00082654 Completed N/A Study of the Emotional Needs of Caregivers of Stem Cell Transplantation Patients March 2002 October 2004
NCT04406623 Completed Phase 1 Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer June 29, 2020 February 2, 2023
NCT00001302 Completed Phase 1 A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 September 1992 June 2002
NCT00842452 Completed Phase 1 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery February 2009 April 2011
NCT01376505 Completed Phase 1 Vaccine Therapy in Treating Patients With Metastatic Solid Tumors June 21, 2011 November 28, 2022
NCT00928642 Completed Phase 2 Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer June 2009 November 2010
NCT03166891 Completed Phase 1/Phase 2 Phase Ib Study of Chiauranib in Patients With Ovarian Cancer December 15, 2017 March 20, 2019
NCT00562003 Completed Phase 1 Safety Study of a Genetically Modified Adenovirus in Ovarian Cancer Patients June 2007 June 2010
NCT02526017 Completed Phase 1 Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers September 8, 2015 November 18, 2019
NCT00002515 Completed Phase 2 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer October 1992 April 2005
NCT00581815 Completed Phase 1 Spectroscopy With Surface Coils and Decoupling February 1997 February 2014
NCT00488202 Completed Advanced Ovarian Cancer and Sexuality Phase 1 May 2007 August 2011
NCT02063464 Completed Blood Collection From People With Ovarian Cancer March 10, 2014 November 16, 2016
NCT00073541 Completed Phase 2 A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer April 2003 August 2004
NCT00102414 Completed Phase 3 Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer September 1999 November 2004
NCT06328491 Completed N/A Erdafitinib in Metastatic Steroid-cell Ovarian Cancer May 30, 2022 August 22, 2022
NCT01237067 Completed Phase 1 Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers February 7, 2011 December 12, 2019
NCT00391118 Completed Phase 2 Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") November 2006 July 2012
NCT02988817 Completed Phase 1/Phase 2 Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors November 23, 2016 November 12, 2021
NCT00507741 Completed Phase 2 Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) August 2007 April 2009
NCT04672460 Completed Phase 1 A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors December 21, 2020 July 22, 2022
NCT03752216 Completed Phase 4 NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. April 3, 2019 December 13, 2022
NCT00342446 Completed A Follow-up Study of Women Evaluated and Treated for Infertility October 1, 1995 January 11, 2023
NCT00987649 Completed Ovarian Cancer Risk Estimation in Patients With Pelvic Mass October 2009 September 2010
NCT03593681 Completed Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy August 27, 2018 February 14, 2020
NCT03759587 Completed Phase 2 Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer December 28, 2018 December 28, 2022
NCT02610075 Completed Phase 1 Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours. December 1, 2015 April 26, 2018
NCT00003732 Completed Phase 2 Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Cancer September 1998 September 2005
NCT01419210 Completed N/A Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer January 2010 September 2015
NCT01370122 Completed Pelvic Floor Disorders in Survivors of Gynecologic Malignancies May 2011 September 2017
NCT00045175 Completed Phase 1 UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer June 2002
NCT00617188 Completed Phase 2 Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer June 2007 July 2008
NCT00055614 Completed Phase 1 Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer May 2002 October 2007
NCT00437307 Completed Phase 3 Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse March 2007 June 2015
NCT00019084 Completed Phase 2 Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer February 1996 May 2003
NCT00005836 Completed Phase 2 Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy February 2000 July 2004
NCT00003297 Completed Phase 1/Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer December 1997 January 2001
NCT01433224 Completed Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression October 2011 May 2016
NCT01570218 Completed N/A Musicotherapy in the Reduction of Fatigue in Women With Breast or Gynecological Cancer Under Radiotherapy February 2010 February 2011
NCT05001347 Completed Phase 2 A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors November 2, 2021 February 8, 2023
NCT00270166 Completed Phase 3 The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy February 1995 May 1998
NCT01239732 Completed Phase 3 A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer December 2010 March 2015
NCT03069872 Completed N/A A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer April 5, 2017 April 30, 2018
NCT00377429 Completed Phase 2 Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy September 2006 February 2008
NCT01444456 Completed Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia October 2011
NCT00291837 Completed Phase 2 CT-2106 for the Second Line Treatment of Ovarian Cancer November 2004 December 2007
NCT00293384 Completed N/A Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant October 2004 February 2012
NCT02878122 Completed Study of Predictive Factors of Chemoresistance in Ovarian Cancer March 2015 March 2020
NCT00608452 Completed Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers July 1995 November 2009
NCT00520013 Completed Phase 2 Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors August 2007 November 2013
NCT00477282 Completed Phase 3 Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer August 2007 June 2013
NCT00291473 Completed Phase 1 Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers July 2005 August 2008
NCT00337233 Completed N/A Yoga in Controlling Symptoms and Reducing Stress in Women With Ovarian Cancer or Breast Cancer January 2004 November 2016
NCT06342934 Completed Radiomics and Machine Learning in the Diagnosis of Ovarian Masses July 22, 2020 December 31, 2023
NCT00003967 Completed Phase 1 Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer September 1999
NCT00075712 Completed Phase 2/Phase 3 Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer September 2003
NCT00129727 Completed Phase 2 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) June 2005 February 2009
NCT05011539 Completed Thiol-disulfide Homeostasis in Patients With Ovarian Cancer April 9, 2021 May 1, 2022
NCT02483104 Completed Phase 1 Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer July 2015 July 2016
NCT03326713 Completed N/A Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project October 1, 2016 August 1, 2020
NCT00429559 Completed Phase 1/Phase 2 Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma June 2006 July 2011
NCT02249013 Completed Phase 2 Short-course HIPEC in Advanced Epithelial Ovarian Cancer February 2015 February 23, 2021
NCT04492007 Completed N/A Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS) November 2, 2020 December 20, 2021
NCT04041128 Completed Early Phase 1 PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer July 23, 2019 June 15, 2021
NCT00101257 Completed Phase 1 Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer October 2004 March 2010
NCT00003413 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer September 1998 February 2001
NCT04823065 Completed Phase 1/Phase 2 4FMFES-PET Imaging of Endometrial and Ovarian Cancers September 1, 2018 April 30, 2024
NCT00006357 Completed Phase 1/Phase 2 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma August 2000
NCT00478387 Completed Ovarian Cancer and Immune Response to Flu Vaccine October 2006 June 2011
NCT02151370 Completed An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer March 2013 September 2013
NCT00027534 Completed Phase 1 Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer January 2002 October 2007
NCT00181688 Completed Phase 2 Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer October 2003 March 2006
NCT00849199 Completed Cancer Screening and Prevention Program for High Risk Women July 2001 January 2018
NCT00787514 Completed FR in Stored Plasma July 2008 February 2011
NCT00489359 Completed Phase 1/Phase 2 Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer July 2005 February 2010
NCT00801320 Completed N/A Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer September 2008 August 2020
NCT01705288 Completed Early Phase 1 Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study January 1, 2013 August 24, 2016
NCT00803569 Completed Phase 1 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers November 14, 2008 January 24, 2011
NCT00006453 Completed Phase 3 Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy September 1999 October 2006
NCT03206645 Completed Phase 1 Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy August 28, 2017 March 31, 2024
NCT03543462 Completed Phase 4 Diaphragmatic Resection And Gynecological Ovarian Neoplasm March 20, 2018 January 11, 2020
NCT00190697 Completed Phase 4 A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment January 2001 April 2007
NCT00281632 Completed Phase 2 A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer March 2006 October 2010
NCT04823871 Completed N/A Early Detection of High Grade Ovarian Cancer Using Uterine Lavage EHUD Study and Duplex Sequencing November 1, 2018 June 30, 2022
NCT00434642 Completed Phase 3 A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma April 2007 July 2013
NCT00626873 Completed Phase 1 Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary January 2007 February 2012
NCT00477386 Completed Phase 1/Phase 2 Trial of Decitabine as a Sensitizer to Carboplatin in Platinum Resistant Recurrent Ovarian Cancer July 2007 September 2013
NCT00588237 Completed Phase 2 Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer August 2006 November 2014
NCT02728622 Completed Phase 3 Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane March 2002 January 2009
NCT02307500 Completed Phase 2 Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy December 2014 August 2020
NCT02824328 Completed A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers June 2016 January 10, 2022
NCT02664389 Completed N/A Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation February 1, 2016 March 15, 2017
NCT00217555 Completed Phase 2 Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer July 2002
NCT03657043 Completed Phase 2 A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) March 20, 2019 February 8, 2022
NCT00004081 Completed Phase 2 Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer July 1999 March 2003
NCT01166737 Completed N/A Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer July 2010 December 31, 2020
NCT01937104 Completed N/A ONSD According to the Position During Laparoscopy September 2013 September 2014
NCT03889171 Completed Comparison to Psychological, Medical and Emotional Influencing Communication and Achievement Factors to Oncogenetics Tests August 2012 September 2018
NCT02490488 Completed Phase 2/Phase 3 Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients April 2014 December 2020
NCT00216112 Completed Phase 2 Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer December 2003 July 2007
NCT00113789 Completed Phase 2 Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer October 2003 April 2005
NCT00019461 Completed Phase 2 Carboxyamidotriazole in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer April 1998 October 2007
NCT00003450 Completed Phase 1 Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer September 1998 January 1999
NCT00003644 Completed Phase 3 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer October 1998
NCT01787656 Completed A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus January 2013 August 2018
NCT00261027 Completed Phase 2 Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer January 2003 September 2007
NCT02019524 Completed Phase 1 Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients September 30, 2013 December 6, 2016
NCT00900679 Completed N/A Effects of a Teaching Intervention With an Advanced Practice Nurse on Quality of Life and Psychosocial and Symptom Distress in Patients With Ovarian Cancer July 2008 February 2010
NCT04066361 Completed N/A OPTimizing Treatment Focused Genetic Testing IN Cancer December 19, 2019 November 30, 2022
NCT00721162 Completed Phase 2 Study of Ramucirumab in Ovarian Cancer August 2008 August 2015
NCT03364673 Completed N/A Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer July 20, 2018 December 5, 2020
NCT05564234 Completed N/A Role of Laparoscopy in Assessing Resectability of Ovarian Cancer December 9, 2019 April 9, 2022
NCT00170573 Completed Phase 2 Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer October 2001 August 2010
NCT00001503 Completed Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease September 19, 1996 June 15, 2023
NCT00964756 Completed Phase 1 A Study of an Infectivity Enhanced Suicide Gene Expressing Adenovirus for Ovarian Cancer in Patients With Recurrent Ovarian and Other Selected Gynecologic Cancers August 2009 April 2012
NCT02000778 Completed Phase 1 EC17 for Intraoperative Imaging in Occult Ovarian Cancer November 2013 November 12, 2014
NCT03056833 Completed Phase 1 Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer June 10, 2017 August 1, 2022
NCT03735680 Completed Phase 2 A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer August 9, 2019 November 18, 2021
NCT00030706 Completed Phase 2 Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer November 2004
NCT00005807 Completed Phase 1 Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer July 2000 August 2004
NCT00517621 Completed Phase 2 Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire February 2006 October 2010
NCT01582906 Completed A Survivorship Care Plan for Gynaecological Cancer Patients August 2011 April 2015
NCT00003308 Completed Phase 2 Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma February 2, 1999
NCT02477644 Completed Phase 3 Platine, Avastin and OLAparib in 1st Line May 6, 2015 March 22, 2022
NCT03784378 Completed Phase 1 Continued Access to RXDX-105 December 14, 2018 September 30, 2020
NCT00735150 Completed Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk March 2008 October 2010
NCT00002717 Completed Phase 3 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer March 1996
NCT01652079 Completed Phase 2 CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer April 2012 March 2018
NCT01248962 Completed Phase 2 Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer November 2010 August 2018
NCT00466986 Completed Phase 2 Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer November 2005 October 2011
NCT00113607 Completed Phase 3 An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer April 2005 November 2010
NCT02163720 Completed Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON) July 10, 2014 September 18, 2018
NCT00844506 Completed Phase 2 p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer October 2008 July 2009
NCT00002750 Completed Phase 1 Melphalan in Patients With Neoplastic Meningitis December 1992 May 2001
NCT00002931 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer February 1997 December 2014
NCT03117933 Completed Phase 2 Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer March 9, 2017 December 31, 2023
NCT00607607 Completed Phase 2 A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer January 2008 January 2012
NCT03656809 Completed Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer October 15, 2015 January 29, 2020
NCT04032600 Completed N/A Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics August 1, 2017 September 9, 2019
NCT00872989 Completed Phase 2 S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer March 2010 May 2014
NCT01105650 Completed Phase 2 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer July 2010 April 2014
NCT02657889 Completed Phase 1/Phase 2 Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer April 15, 2016 September 17, 2021
NCT00003425 Completed Phase 1/Phase 2 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect December 1997
NCT02354131 Completed Phase 1/Phase 2 Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer February 15, 2015 December 15, 2021
NCT03470805 Completed Phase 2 Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma June 21, 2018 July 27, 2022
NCT00006036 Completed Phase 1 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors March 22, 2000 December 21, 2009
NCT00683241 Completed Phase 1 A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer November 2007 December 2009
NCT00005023 Completed Phase 1 Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer March 1999 January 2001
NCT02054351 Completed Phase 1 Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) February 6, 2014 October 28, 2015
NCT00132522 Completed Phase 1 EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide May 2005 April 2009
NCT00340210 Completed Extended Follow-up of Columbia, MO Serum Bank Participants January 14, 1999 September 2, 2014
NCT03695380 Completed Phase 1 A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer January 9, 2019 July 12, 2023
NCT04234243 Completed HIPEC in Ovarian Cancer, Case-Controls Study With 10-years Follow up August 1, 2007 August 31, 2019
NCT00003636 Completed Phase 3 Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer September 1998
NCT02327078 Completed Phase 1/Phase 2 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) November 26, 2014 June 16, 2020
NCT05868889 Completed Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD October 21, 2021 June 16, 2022
NCT03490669 Completed Phase 1 Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors May 21, 2018 September 23, 2019
NCT00883181 Completed A Study of Neutropenia and Anemia Management in Patients With Solid Tumors Receiving Myelotoxic Chemotherapy November 2006 September 2014
NCT01891344 Completed Phase 2 A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) October 30, 2013 September 28, 2021
NCT00486707 Completed Ovarian Cancer Patient Questionnaire on Genetic Testing June 2007 October 2008
NCT02269293 Completed Phase 1 Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers October 13, 2014 April 20, 2021
NCT00504257 Completed Phase 2 Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma March 2007 October 2012
NCT02317705 Completed Phase 2 Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer December 2014 November 2015
NCT00267072 Completed Ovarian Screening Study June 2001 May 2010
NCT00003523 Completed Phase 2 Aminocamptothecin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Cancer of the Peritoneum January 1999 October 2007
NCT00750386 Completed Phase 1/Phase 2 Paclitaxel and Carboplatin Combination as 1st Line Treatment in Ovarian Carcinomas January 2008 March 2011
NCT00096239 Completed Phase 2 CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer December 2004 February 2005
NCT01556841 Completed Phase 2 The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer November 2013 April 19, 2019
NCT01523678 Completed Phase 2 Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers February 2012 August 14, 2018
NCT00699907 Completed Phase 2 Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer January 2005 November 2014
NCT00019916 Completed Phase 1/Phase 2 Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer June 2000 July 2006
NCT00381888 Completed Phase 2 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer January 2007 January 2009
NCT00170625 Completed Phase 1/Phase 2 Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer June 2004 September 2010
NCT03604653 Completed Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers May 15, 2018 May 1, 2021
NCT01033123 Completed Phase 2 A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer December 2009 February 2012
NCT01272817 Completed N/A Nonmyeloablative Allogeneic Transplant October 2001 October 2015
NCT02737787 Completed Phase 1 A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer April 2016 April 6, 2023
NCT00020696 Completed Phase 2 Tirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer June 2001
NCT03936270 Completed Phase 2 Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer March 5, 2020 May 2, 2023
NCT00510653 Completed Phase 2 Gleevec Study for Patients With Ovarian Cancer March 2002 February 2012
NCT00058435 Completed Phase 1 Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer December 2002 March 2004
NCT00523380 Completed Phase 2 Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer October 4, 2007 January 7, 2009
NCT00433602 Completed Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors November 2006
NCT01679483 Completed N/A Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer September 2012 November 2015
NCT00944944 Completed Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema July 2009 January 2010
NCT00003670 Completed Phase 2 Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer October 1998 January 2001
NCT02039388 Completed N/A Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma November 2013 December 31, 2021
NCT02004093 Completed Phase 2 A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer December 2005 September 2008
NCT00006155 Completed Phase 1 SU5416 and Carboplatin to Treat Ovarian Cancer August 2000 April 2001
NCT02585362 Completed N/A Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program March 2016 October 2018
NCT00712218 Completed N/A Lymphadenectomy In Ovarian Neoplasms December 2008 December 2017
NCT00072410 Completed Phase 1 Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer November 2003 November 15, 2006
NCT00004177 Completed Phase 1/Phase 2 Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer August 1999
NCT01048814 Completed Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases August 2009 June 2011
NCT00501644 Completed Phase 2 Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer January 2003 January 2009
NCT00189358 Completed Phase 2 A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy
NCT00474994 Completed Phase 2 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas April 2007 November 2010
NCT03075462 Completed Phase 1 A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients March 9, 2017 December 13, 2021
NCT00217529 Completed Phase 1/Phase 2 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer June 2004
NCT03267589 Completed Phase 2 Trial in Patients With Relapsed Ovarian Cancer May 14, 2018 October 19, 2021
NCT00401674 Completed Phase 2 MITO-5: Weekly Carboplatin and Paclitaxel as First Line Chemotherapy for Elderly Patients With Ovarian Cancer June 2003 June 2008
NCT01276548 Completed Phase 2 A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer October 2009 September 2012
NCT00024258 Completed Phase 2 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors March 2001 May 2009
NCT01047891 Completed Phase 2 Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer January 2010 February 2015
NCT00227721 Completed Phase 2 Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer February 2004 February 2017
NCT01931644 Completed At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions July 2013 April 2024
NCT01709175 Completed N/A Strength Training Study for Survivors of Breast and Gynecologic Cancer November 2012 January 2015
NCT04939701 Completed Phase 1/Phase 2 Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants January 11, 2022 June 1, 2023
NCT00816764 Completed Phase 1 A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer October 2008 June 2010
NCT00716976 Completed Phase 3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy June 23, 2008 June 30, 2021
NCT00003695 Completed Phase 3 Chemotherapy With or Without Surgery in Treating Patients With Stage II or Stage III Ovarian Cancer May 1998 January 2001
NCT03464201 Completed Phase 2 Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study April 13, 2018 November 11, 2020
NCT01350908 Completed N/A Study of Circulating Tumoral DNA in Ovarian Cancer April 2011 December 2015
NCT02421588 Completed Phase 3 Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients May 2015 October 12, 2018
NCT01936363 Completed Phase 2 Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer September 30, 2013 November 30, 2017
NCT02221076 Completed N/A Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures. July 2014 April 18, 2016
NCT00010283 Completed Phase 1/Phase 2 Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon July 2000 July 2002
NCT02948075 Completed Phase 2 Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy September 2015 June 16, 2017
NCT01059643 Completed Phase 2 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck April 2011 December 2012
NCT06253559 Completed Clinical and Pathological Characteristics of Women With Ovarian Cancers in Syria January 1, 2017 December 24, 2023
NCT02144311 Completed N/A Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics May 2014 June 15, 2020
NCT00002641 Completed Phase 3 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma February 1995 June 2012
NCT00262990 Completed Phase 3 Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer November 2005
NCT03314935 Completed Phase 1/Phase 2 A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors November 21, 2017 November 28, 2022
NCT00340600 Completed Continuation of Follow-up of DES-Exposed Cohorts March 18, 1998 November 13, 2020
NCT01572467 Completed Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors April 2012
NCT00900406 Completed Collecting and Storing Tissue and DNA Samples From Patients Undergoing a Donor Stem Cell Transplant January 2007 March 2010
NCT00002894 Completed Phase 3 Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer March 1996 June 2003
NCT00431054 Completed Phase 1 Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer February 2007 May 2012
NCT02855944 Completed Phase 3 ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients March 1, 2017 September 16, 2022
NCT01188876 Completed Phase 1/Phase 2 Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer August 2010 July 2017
NCT00004065 Completed Phase 1 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer July 1999 March 2005
NCT00319748 Completed Phase 2 Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers April 2006 December 2008
NCT02963831 Completed Phase 1/Phase 2 A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies September 7, 2017 June 25, 2022
NCT04122937 Completed Defining Inflammation Related to Peritoneal Carcinomatosis in Women With Ovarian or Colon Cancer. March 1, 2017 March 30, 2019
NCT01738269 Completed Elecsys HE4 Chinese Reference Value Study November 2012 May 2013
NCT04458168 Completed N/A Feasibility and Evaluation of a Self-care App to Enhance Purposeful Living June 28, 2021 December 10, 2022
NCT00002943 Completed Phase 2 Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer February 1993 August 2007
NCT02560818 Completed N/A Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer October 2015 October 2020
NCT03229122 Completed Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA December 26, 2016 July 6, 2018
NCT03719326 Completed Phase 1 A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies October 15, 2018 July 2, 2021
NCT01031381 Completed Phase 2 Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer September 2010 December 2014
NCT01851928 Completed Validation of a Nutrition Screening Tool July 2011 March 2013
NCT00003944 Completed Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer August 1998 February 2003
NCT00164658 Completed Phase 1 Evaluating Tools for Health Promotion and Disease Prevention September 2005 October 2007
NCT00293293 Completed N/A Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine May 2005 January 2010
NCT00445965 Completed Phase 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer January 2006 February 1, 2023
NCT00006391 Completed Phase 1 Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer August 2000
NCT04330040 Completed Phase 4 Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer May 30, 2020 September 30, 2022
NCT00157573 Completed Phase 2 GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer December 2004 April 2010
NCT03901118 Completed Phase 2 Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer July 1, 2019 December 18, 2020
NCT00004166 Completed Phase 3 Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy October 1999 January 2003
NCT00318370 Completed Phase 2 Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy May 2006 June 2010
NCT00277160 Completed Phase 4 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer June 2002 January 2005
NCT00001806 Completed Phase 3 Methods in Education for Breast Cancer Genetics April 6, 1999 December 6, 2017
NCT00433407 Completed N/A T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors August 2005
NCT03378297 Completed Early Phase 1 IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC May 4, 2018 January 5, 2023
NCT06403072 Completed (GI-RADS) in Preoperative Evaluation of Adnexal Masses June 1, 2021 January 30, 2023
NCT03790423 Completed Phase 1 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer January 3, 2019 November 18, 2019
NCT00030446 Completed Phase 2 Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer January 10, 2002 December 21, 2009
NCT00003795 Completed Quality of Life in Survivors of Gynecologic Cancer April 1999
NCT01033292 Completed Phase 2 A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer December 2009 December 2012
NCT02475772 Completed Phase 1 A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis November 2016 May 2018
NCT05504174 Completed Detection of Circulating Tumor DNA Through Liquid Biopsies in Ovarian Cancer Patients and Evaluation of Prognostic and Predictive Values of Circulating Tumor DNA Assay. September 10, 2019 June 30, 2022
NCT00419510 Completed N/A Genetic Counseling in African American Women February 2003 September 2012
NCT06063343 Completed Phase 1 Evaluation of Safety, Tolerability, Pharmacokinetics, Food Effect and Interaction With Midazolam in Healthy Volunteers After Oral Single and Multiple Ascending Dosing of KAND145 November 9, 2023 April 8, 2024
NCT00003408 Completed Phase 2 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer April 1998 March 2000
NCT00751205 Completed Phase 2 Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) August 2008 August 2010
NCT00098800 Completed N/A Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries October 2004 November 2006
NCT00739661 Completed Phase 2 A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission December 2008 November 2010
NCT00002895 Completed Phase 3 Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer June 1996 October 2010
NCT03028519 Completed Early Phase 1 Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer January 31, 2017 December 30, 2020
NCT00976911 Completed Phase 3 AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer October 29, 2009 July 9, 2014
NCT00648102 Completed Phase 1 Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian Cancer January 2006 December 2009
NCT00003120 Completed Phase 3 S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission November 1997 November 2012
NCT00189553 Completed Phase 3 Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse April 2005 June 2012
NCT03519165 Completed N/A Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery June 2016 September 2019
NCT06436248 Enrolling by invitation Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian Cancer July 2024 October 2027
NCT03762733 Enrolling by invitation Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies January 4, 2022 December 29, 2028
NCT05721326 Enrolling by invitation N/A Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition May 1, 2023 December 1, 2024
NCT04421963 Enrolling by invitation Phase 3 Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib August 4, 2020 December 10, 2024
NCT04699006 Enrolling by invitation Efficacy and Adverse Effects of Olaparib in Ovarian Cancer. January 21, 2021 January 1, 2026
NCT05904730 Enrolling by invitation Phase 1 Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations July 11, 2023 November 9, 2024
NCT05318625 Enrolling by invitation N/A A Prospective Study to Evaluate the Clinical Performance and Safety of the SIRIUS Endoscope System in Laparoscopic Gynecological Surgery. January 10, 2023 July 2024
NCT06386653 Enrolling by invitation Phase 1 Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1 April 14, 2024 December 31, 2024
NCT06120309 Enrolling by invitation New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer November 1, 2023 December 31, 2024
NCT05223218 Enrolling by invitation Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study August 25, 2021 December 2023
NCT03554434 No longer available An Expanded Access Program for AM0010 (Pegilodecakin)
NCT06188455 Not yet recruiting Phase 3 Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer December 1, 2024 December 1, 2026
NCT05583799 Not yet recruiting Efficacy and Adverse Effects of Niraparib in Ovarian Cancer. October 15, 2022 September 30, 2025
NCT06180356 Not yet recruiting Phase 2 Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression August 2024 November 2025
NCT06412120 Not yet recruiting Phase 4 Study Evaluating Safety, Tolerability, and Metabolism of Niraparib September 1, 2024 September 1, 2029
NCT06018935 Not yet recruiting A Cohort Establishment Study of Total Management of Ovarian Cancer January 1, 2024 September 1, 2025
NCT05976932 Not yet recruiting Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer August 2023 October 2024
NCT05475184 Not yet recruiting Phase 2 A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor August 1, 2022 June 2025
NCT06392997 Not yet recruiting Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology June 2024 June 2026
NCT06376253 Not yet recruiting Phase 1 A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers September 6, 2024 August 30, 2030
NCT06465069 Not yet recruiting Phase 1 A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors June 2024 May 2027
NCT06304922 Not yet recruiting BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary April 1, 2024 April 1, 2026
NCT05805358 Not yet recruiting Phase 2 Hyperpolarized 13C MRI for Cancer Immunotherapy November 1, 2023 July 31, 2026
NCT05921149 Not yet recruiting N/A Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer May 25, 2024 June 1, 2031
NCT06383507 Not yet recruiting Phase 1 A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors April 22, 2024 April 21, 2029
NCT05749211 Not yet recruiting N/A Huaier Granule in Combination With Nilaparil in Therapy Patients With Stage III/IV BRCA Wild-type Ovarian Cancer May 2023 December 2025
NCT06430541 Not yet recruiting Phase 1 A Phase 1b Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence December 2024 December 2028
NCT05375526 Not yet recruiting N/A Magtrial: Magtrace® as Tracer for Sentinel Lymph Node Detection in Early Stage Epithelial Ovarian Cancer June 1, 2022 October 1, 2024
NCT05641506 Not yet recruiting Phase 2 A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer December 2022 May 2025
NCT05801796 Not yet recruiting Appraising Medical Trial Experiences of Ovarian Cancer Patients April 2024 April 2026
NCT06063070 Not yet recruiting Phase 2 First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer October 18, 2023 October 30, 2027
NCT06440018 Not yet recruiting INSPIRE: A Multi-Cancer Early Detection Study June 20, 2024 February 28, 2025
NCT06305299 Not yet recruiting Phase 1 Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells July 2024 March 2026
NCT04640480 Not yet recruiting Phase 1 Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors June 21, 2024 June 30, 2025
NCT05200260 Not yet recruiting Phase 2 Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer February 2022 February 2027
NCT06268665 Not yet recruiting Phase 2 Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy February 28, 2024 June 2027
NCT04520139 Not yet recruiting Phase 1/Phase 2 Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT December 2024 December 2026
NCT06321484 Not yet recruiting Phase 1 Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer May 2024 October 31, 2031
NCT05187208 Not yet recruiting Phase 4 PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer January 2022 December 2025
NCT06161272 Not yet recruiting Phase 2 Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi December 10, 2023 January 10, 2026
NCT05460000 Not yet recruiting Phase 2 A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy June 1, 2024 May 1, 2032
NCT05931055 Not yet recruiting The Effectiveness of Liquid Biopsy in Differential Diagnosis and Early Screening of Epithelial Ovarian Cancer January 1, 2024 January 1, 2032
NCT05669768 Not yet recruiting Phase 2 Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy January 1, 2023 December 1, 2024
NCT04214782 Not yet recruiting N/A Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm October 1, 2022 October 1, 2024
NCT04451369 Not yet recruiting N/A Connected Prehabilitation Program During Neo Adjuvant Chemotherapy May 2021 September 2027
NCT05965141 Not yet recruiting Phase 1/Phase 2 Aribulin Combined With Carboplatin and Bevacizumab in the Treatment of Ovarian Cancer August 1, 2023 June 1, 2025
NCT05044871 Not yet recruiting Phase 2 Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer January 1, 2023 December 1, 2027
NCT06127446 Not yet recruiting The Registry of Genetic Alterations of Taiwan Ovarian Cancer November 15, 2023 December 31, 2028
NCT05052632 Not yet recruiting Evaluating a New Gonadotoxic Risk Stratification System April 2024 May 2028
NCT05952453 Not yet recruiting Phase 2 Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro May 26, 2024 September 30, 2025
NCT06412510 Not yet recruiting Phase 1/Phase 2 Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT June 1, 2024 February 10, 2025
NCT06211023 Not yet recruiting Phase 2/Phase 3 A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer February 15, 2024 June 15, 2026
NCT05567601 Not yet recruiting Phase 1 Doxil/Caelyx BE Study November 30, 2023 April 1, 2024
NCT06238284 Not yet recruiting HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China January 26, 2024 May 31, 2024
NCT06366490 Not yet recruiting Phase 1 Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer June 1, 2024 March 1, 2025
NCT05597527 Not yet recruiting Phase 2 Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer November 1, 2022 May 31, 2025
NCT06283875 Not yet recruiting The Exploration of Personalized ctDNA Based MRD in the Clinical Significance of Cervical Cancer March 1, 2024 January 30, 2029
NCT03818282 Not yet recruiting Phase 2 Efficacy and Safety of Paclitaxel for Injection (Albumin-bound) for First-line Chemotherapy of Ovarian Cancer March 1, 2019 December 31, 2024
NCT06342986 Not yet recruiting Phase 1 Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer August 1, 2024 June 30, 2029
NCT06040970 Not yet recruiting Phase 1/Phase 2 Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer October 2024 September 7, 2026
NCT05684731 Not yet recruiting Phase 1 Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer February 1, 2023 June 1, 2026
NCT06399757 Not yet recruiting Phase 1/Phase 2 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors May 2024 May 2027
NCT06433219 Not yet recruiting Phase 2 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) July 26, 2024 January 25, 2028
NCT05043402 Not yet recruiting Phase 3 A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer November 30, 2022 August 15, 2024
NCT06329323 Not yet recruiting SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours April 14, 2024 April 2028
NCT05496517 Not yet recruiting Ovarian Cancer Individualized Scoring System Scoring System November 11, 2022 November 22, 2023
NCT06394492 Not yet recruiting Phase 3 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer May 31, 2024 December 31, 2026
NCT06457997 Not yet recruiting Phase 1 A Study of PHN-010 in Patients With Advanced Solid Tumors July 2024 July 2027
NCT05450055 Not yet recruiting N/A Intraperitoneal Lidocaine in Ovarian Cancer Surgery July 18, 2022 July 30, 2029
NCT04828616 Not yet recruiting Phase 2 Study of DP303c Injection in Patients With Advanced Ovarian Cancer July 2021 July 2024
NCT06284343 Not yet recruiting Development and Validation of a Risk Prediction Model for Venous Thromboembolism in Gynecological Cancer Patients Undergoing Systemic Antineoplastic Treatment: The Gynecological Cancer Associated Thrombosis (GynCAT) Study April 1, 2024 September 30, 2026
NCT05316376 Not yet recruiting Phase 2 Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial May 1, 2022 April 30, 2025
NCT06139783 Not yet recruiting N/A Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors September 2024 August 2025
NCT06377267 Recruiting Phase 2 Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) February 6, 2024 September 2025
NCT06458361 Recruiting Identification of Risk Factors and Construction of Prediction Model for Postoperative Intestinal Anastomotic Leakage in Ovarian Cancer January 1, 2018 November 1, 2024
NCT04294927 Recruiting N/A TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention March 1, 2020 February 17, 2040
NCT06253520 Recruiting Phase 1 Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer May 16, 2024 June 15, 2033
NCT05827614 Recruiting Phase 1 Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications March 24, 2023 September 30, 2027
NCT06037213 Recruiting A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib August 23, 2023 January 31, 2024
NCT05048407 Recruiting N/A Sirius in Gynaecological Laparoscopic Surgery May 30, 2023 June 30, 2024
NCT05704621 Recruiting Phase 2 Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance December 1, 2023 December 28, 2028
NCT06182917 Recruiting Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients October 1, 2023 June 30, 2026
NCT01977274 Recruiting N/A Predictive Clinical and Biological Parameters in Gynecological Cancer December 2013 December 2033
NCT04657068 Recruiting Phase 1/Phase 2 A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors December 13, 2020 June 2025
NCT05129969 Recruiting Registry Platform Ovarian and Endometrial Cancer November 25, 2021 December 2027
NCT06103916 Recruiting Prospective RegIstration Of the peRformance of the IoTa ADNEX Model in Dutch gYnaecological Practice July 15, 2022 May 2028
NCT05226507 Recruiting Phase 1 A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer December 31, 2021 June 2025
NCT06250686 Recruiting N/A Exercise and Nutrition Intervention in Ovarian Cancer January 10, 2024 December 31, 2025
NCT04188652 Recruiting Diagnosing Ovarian Cysts - the DOC Study January 1, 2020 December 2025
NCT05059782 Recruiting N/A Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer October 10, 2021 September 1, 2024
NCT05259696 Recruiting Phase 1/Phase 2 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) February 11, 2022 June 2025
NCT04751435 Recruiting N/A Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients November 16, 2021 August 31, 2026
NCT05922930 Recruiting Phase 1/Phase 2 Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer October 11, 2023 July 1, 2028
NCT05099978 Recruiting Asian Multicenter Prospective Study of ctDNA Sequencing November 1, 2021 December 31, 2024
NCT06257264 Recruiting Phase 1 A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors February 28, 2024 December 31, 2026
NCT05605535 Recruiting Phase 2 Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer February 7, 2023 May 15, 2026
NCT04473833 Recruiting N/A Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer December 19, 1988 December 31, 2025
NCT05649072 Recruiting N/A Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics. November 18, 2022 February 2, 2027
NCT02632448 Recruiting Phase 1/Phase 2 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer May 16, 2016 September 30, 2025
NCT05239143 Recruiting Phase 1 P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors February 15, 2022 April 2039
NCT04945187 Recruiting N/A Patient-Reported Outcomes Among Women Wtih Gynecological Cancer (The CONNECT Study) May 17, 2021 February 1, 2024
NCT06249308 Recruiting Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC ) December 18, 2023 December 31, 2026
NCT04282356 Recruiting Phase 2 Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer September 15, 2020 December 2030
NCT05056077 Recruiting N/A Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit) October 21, 2021 December 31, 2027
NCT05494580 Recruiting Phase 1/Phase 2 Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer September 22, 2022 August 10, 2025
NCT05429970 Recruiting N/A A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) June 17, 2022 June 17, 2025
NCT04981119 Recruiting Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing October 29, 2021 December 2026
NCT05574673 Recruiting Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype December 1, 2022 December 1, 2028
NCT06240598 Recruiting Phase 2 A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy January 26, 2024 January 2026
NCT04414683 Recruiting Factors Affecting the Prognosis of Early Ovarian Cancer April 13, 2020 December 31, 2024
NCT03787056 Recruiting N/A Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients December 4, 2018 January 4, 2028
NCT05646680 Recruiting N/A A Performance Study of (Opportunistic) Salpingectomy December 9, 2022 January 30, 2026
NCT05640024 Recruiting Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors November 6, 2022 October 30, 2025
NCT05467670 Recruiting Phase 2 Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer December 16, 2022 December 2027
NCT05498597 Recruiting Phase 1 AMT-151 in Patients With Selected Advanced Solid Tumours January 25, 2023 October 30, 2024
NCT03150121 Recruiting N/A Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage June 29, 2014 December 31, 2024
NCT03958240 Recruiting N/A Deciphering Mechanisms Underlying Cancer Immunogenicity January 17, 2020 September 2029
NCT05446545 Recruiting Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer September 1, 2021 December 31, 2026
NCT05000294 Recruiting Phase 1/Phase 2 Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types December 7, 2021 December 2025
NCT04560452 Recruiting Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese Patients March 15, 2021 December 31, 2025
NCT05974150 Recruiting Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring July 19, 2023 December 31, 2024
NCT05316129 Recruiting Phase 1 Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer April 28, 2022 March 2029
NCT05030805 Recruiting Transcriptional Map of Ovarian Cancer at the Single Cell Level May 1, 2022 April 2030
NCT06264921 Recruiting Phase 1 A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors February 23, 2024 May 2025
NCT06118307 Recruiting Shanghai Ovarian Cancer and Family Care Project January 1, 2013 October 13, 2028
NCT06085404 Recruiting N/A Patients Derived Organoids in Ovarian Cancer December 20, 2021 December 20, 2023
NCT05693987 Recruiting Early Detection of Ovarian Cancer Using Plasma Cell-free DNA Fragmentomics (Prospective Study) November 1, 2022 April 30, 2023
NCT05829057 Recruiting Phase 1 The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 May 23, 2023 June 21, 2025
NCT02917798 Recruiting Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes July 12, 2016 September 2025
NCT05903807 Recruiting Phase 2 [68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer November 17, 2023 January 1, 2035
NCT05633836 Recruiting N/A MicroFluO: FLUorescence-guided Surgery for Ovarian Cancer May 2023 February 2024
NCT05156892 Recruiting Phase 1 Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer September 4, 2022 January 1, 2025
NCT04742075 Recruiting Phase 2 Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer December 15, 2021 December 15, 2026
NCT03287271 Recruiting Phase 1/Phase 2 ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK February 6, 2018 October 2024
NCT03842982 Recruiting Phase 3 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) April 1, 2019 August 1, 2028
NCT05065021 Recruiting Phase 2 Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor February 23, 2023 June 6, 2025
NCT04122235 Recruiting N/A The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study November 18, 2019 December 31, 2030
NCT05523700 Recruiting N/A Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2) October 17, 2023 October 1, 2028
NCT05864144 Recruiting Phase 1/Phase 2 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors May 31, 2023 June 2027
NCT06238479 Recruiting Phase 1 A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors March 5, 2024 March 4, 2027
NCT05739981 Recruiting Phase 1/Phase 2 Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer February 10, 2023 January 30, 2028
NCT05113368 Recruiting Phase 2 Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer June 28, 2022 December 1, 2024
NCT05518253 Recruiting Phase 1 A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors May 30, 2022 May 30, 2025
NCT04520074 Recruiting Phase 3 Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2) October 8, 2021 September 2030
NCT06363123 Recruiting Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis March 29, 2024 April 2025
NCT05431530 Recruiting Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer June 22, 2022 May 31, 2027
NCT05211557 Recruiting Phase 1/Phase 2 Study of Fully Human B7H3 CAR-T in Treating Recurrent Malignant Ovarian Cancer November 16, 2021 August 31, 2026
NCT05287451 Recruiting N/A Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study May 10, 2022 December 26, 2026
NCT05606692 Recruiting Phase 4 Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics) November 23, 2022 September 30, 2027
NCT05427214 Recruiting N/A Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy August 19, 2022 October 2, 2024
NCT03010124 Recruiting N/A Prognostic and Predictive Biomarkers in Ovarian Cancers September 26, 2016 September 2032
NCT03410784 Recruiting Phase 2 Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer April 1, 2018 December 2024
NCT05738902 Recruiting Adherence and Compliance to ERAS in Gynecological Surgery May 30, 2023 March 31, 2025
NCT05427487 Recruiting Phase 1 Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours February 17, 2023 September 1, 2024
NCT04969835 Recruiting Phase 1 A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours July 16, 2021 June 30, 2023
NCT04575961 Recruiting Phase 2 Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer February 22, 2022 November 1, 2026
NCT06317610 Recruiting Artificial Intelligence Model for Growth Prediction of Ovarian Cancer Organoids January 1, 2022 May 30, 2024
NCT04884360 Recruiting Phase 3 D9319C00001- 1L OC Mono Global RCT May 31, 2021 July 2, 2025
NCT05092763 Recruiting N/A Prehabilitation During the Neoadjuvant Window of Opportunity in Older Women With Ovarian Cancer December 10, 2021 August 31, 2024
NCT04606914 Recruiting Phase 2 Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer May 27, 2021 May 31, 2028
NCT06395519 Recruiting Phase 1 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies May 2024 December 2026
NCT05086692 Recruiting Phase 1/Phase 2 A Beta-only IL-2 ImmunoTherapY Study August 27, 2021 December 30, 2026
NCT06184867 Recruiting Early Phase 1 Choices About Genetic Testing And Learning Your Risk With Smart Technology October 26, 2023 January 31, 2025
NCT04180371 Recruiting Phase 1/Phase 2 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression November 7, 2019 December 31, 2024
NCT04830709 Recruiting Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer June 15, 2021 December 31, 2031
NCT05788484 Recruiting Phase 1 A Study of CDX-585 in Patients With Advanced Malignancies May 11, 2023 February 2026
NCT03412877 Recruiting Phase 2 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer September 6, 2018 March 23, 2028
NCT06324175 Recruiting Spatial Radiogenomics of Ovarian Cancer: Implementation of a Lesion-specific 3D-printed Mould Pipeline in the Clinical Workflow for Image-guided Tissue Multi-sampling of Ovarian Tumours February 1, 2024 December 31, 2026
NCT05051722 Recruiting Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer August 3, 2021 December 30, 2025
NCT06459271 Recruiting N/A Feasibility of CALM in Patients With Ovarian Cancer June 10, 2024 August 10, 2025
NCT05349227 Recruiting N/A Comprehensive Outcomes for After Cancer Health June 23, 2022 December 2025
NCT06071286 Recruiting N/A SEQUENTIAL PROFILING OF TUMOR-DERIVED CIRCULATING CELL-FREE DNA (ctDNA) IN ADVANCED OVARIAN CANCER PATIENTS November 1, 2023 November 1, 2025
NCT06215950 Recruiting Phase 1 A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer January 10, 2024 December 31, 2027
NCT03872947 Recruiting Phase 1 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors April 26, 2019 March 2025
NCT05886075 Recruiting Early Phase 1 A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors March 30, 2023 March 2025
NCT06229522 Recruiting Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA). November 16, 2023 December 31, 2037
NCT05866679 Recruiting Phase 1 Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging April 12, 2024 August 31, 2028
NCT06437353 Recruiting Phase 2 Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer May 25, 2024 October 30, 2027
NCT04140526 Recruiting Phase 1/Phase 2 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC September 16, 2020 December 31, 2027
NCT03540017 Recruiting Phase 1 HIPEC After Initial CRS in Patients Who Have Received NACT March 12, 2019 July 5, 2025
NCT01034033 Recruiting Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples August 2001 January 2099
NCT05071937 Recruiting Phase 2 ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer April 13, 2023 March 1, 2031
NCT02884648 Recruiting Phase 2 Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery November 15, 2016 February 1, 2025
NCT05215574 Recruiting Phase 1 Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors March 31, 2022 March 2026
NCT05272462 Recruiting Phase 2 Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer December 13, 2021 December 31, 2024
NCT06048367 Recruiting Phase 1 Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor October 14, 2022 February 29, 2024
NCT06014190 Recruiting Phase 2 HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer December 18, 2023 December 31, 2027
NCT04644068 Recruiting Phase 1/Phase 2 Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies November 12, 2020 December 15, 2026
NCT04997096 Recruiting N/A Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy April 2, 2022 April 30, 2025
NCT05989724 Recruiting Phase 1 A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors September 19, 2023 March 2026
NCT06152731 Recruiting Phase 2 HRD Tests for Ovarian cancER February 15, 2024 June 2031
NCT02288676 Recruiting DOvEEgene: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics January 2014 October 2026
NCT04066335 Recruiting Study to Evaluate the Safety of Nanoxel M Inj. September 18, 2019 August 2024
NCT05955105 Recruiting Phase 1/Phase 2 A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies July 25, 2023 July 24, 2026
NCT06303505 Recruiting Phase 1/Phase 2 FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC May 2024 January 2027
NCT05206890 Recruiting A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer January 14, 2022 December 31, 2032
NCT03556228 Recruiting Phase 1 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma June 8, 2018 June 2026
NCT05961124 Recruiting Phase 2 Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer August 21, 2023 September 2027
NCT06447064 Recruiting Cancer Loyalty Card Study 2 (CLOCS-2) April 29, 2024 March 31, 2027
NCT05572684 Recruiting Phase 1/Phase 2 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors October 6, 2022 November 2025
NCT05983276 Recruiting Phase 2 Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer November 16, 2023 August 28, 2031
NCT04710797 Recruiting N/A Lymphadenectomy in Early Ovarian Cancer January 31, 2021 December 31, 2028
NCT01441089 Recruiting Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis May 21, 2012
NCT05080556 Recruiting Phase 2 Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer May 24, 2023 November 1, 2027
NCT06380660 Recruiting Phase 1/Phase 2 Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors March 22, 2024 March 21, 2029
NCT06051695 Recruiting Phase 1/Phase 2 A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression April 3, 2024 June 2029
NCT04770376 Recruiting Evaluation of the Predictive Value of Blood Levels of Angiopoietin 1 and Endothelial Internal Tunica Cell Kinase 2 in Patients With Ovarian Cancer Treated With Chemotherapy Associated to Bevacizumab October 12, 2020 December 2023
NCT05697198 Recruiting PRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine April 19, 2021 September 2024
NCT05472532 Recruiting N/A Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture) February 14, 2023 December 14, 2024
NCT04511871 Recruiting Phase 1 A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors July 9, 2020 March 29, 2025
NCT03746431 Recruiting Phase 1/Phase 2 A Phase 1/2 Study of [225Ac]-FPI-1434 Injection January 17, 2019 June 2026
NCT06307249 Recruiting Phase 1 Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA February 15, 2023 December 2027
NCT04284969 Recruiting N/A PROADAPT-ovary/EWOC-2 June 3, 2021 March 3, 2026
NCT05468190 Recruiting Phase 1 A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T July 17, 2022 July 17, 2025
NCT05142033 Recruiting Avera Cancer Sequencing and Analytics Protocol (ASAP) November 1, 2021 December 31, 2026
NCT02830724 Recruiting Phase 1/Phase 2 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers April 6, 2017 January 1, 2028
NCT05857397 Recruiting A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America July 21, 2023 April 30, 2025
NCT04847063 Recruiting Phase 1 Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies October 19, 2021 December 30, 2031
NCT05198804 Recruiting Phase 1/Phase 2 A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer January 27, 2022 November 2023
NCT05032040 Recruiting Phase 2 A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies July 21, 2022 May 30, 2025
NCT05458973 Recruiting Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation. October 31, 2017 October 2024
NCT05360680 Recruiting Phase 1 A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers June 14, 2022 December 2026
NCT03917043 Recruiting Phase 1 APG-2449 in Patients With Advanced Solid Tumors May 27, 2019 February 2025
NCT05715216 Recruiting Phase 2 EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer March 24, 2023 April 30, 2025
NCT05813509 Recruiting N/A Individualized Precision Treatment Based on Ovarian Cancer Organoid Model December 1, 2022 February 1, 2025
NCT06120972 Recruiting Phase 2 Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency January 17, 2024 December 31, 2029
NCT04768270 Recruiting The Culture of Ovarian Cancer Organoids and Drug Screening April 12, 2022 December 31, 2024
NCT05856409 Recruiting Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence May 10, 2023 December 31, 2025
NCT05848739 Recruiting Phase 1 A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors June 5, 2023 May 31, 2027
NCT05420545 Recruiting Phase 1 A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors December 31, 2021 December 31, 2024
NCT05801783 Recruiting Early Phase 1 A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer December 2, 2022 December 2, 2025
NCT06251947 Recruiting Phase 2 Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen April 15, 2024 December 2026
NCT05636111 Recruiting Phase 1 Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer July 12, 2023 July 31, 2026
NCT05001282 Recruiting Phase 1/Phase 2 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) September 13, 2021 June 15, 2025
NCT06222008 Recruiting Study on Symptom Clusters During Chemotherapy in Ovarian Cancer Patients With Different Chinese Medicine Constitution January 30, 2022 June 30, 2024
NCT05708950 Recruiting Phase 1/Phase 2 A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) March 3, 2023 December 31, 2024
NCT04585750 Recruiting Phase 1/Phase 2 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) October 29, 2020 July 14, 2026
NCT05123807 Recruiting Phase 2 Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) January 7, 2022 February 2, 2027
NCT02012699 Recruiting Integrated Cancer Repository for Cancer Research November 1, 2013 December 2099
NCT05697601 Recruiting Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools February 28, 2023 June 30, 2024
NCT04502602 Recruiting Phase 1 Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer August 24, 2020 May 31, 2029
NCT03702309 Recruiting Liquid Biopsy Evaluation and Repository Development at Princess Margaret August 3, 2017 July 6, 2024
NCT05953883 Recruiting N/A PROTEOGENOMIC SIGNATURES ANALYSIS IN OVARIAN CANCER November 17, 2022 March 17, 2024
NCT05812027 Recruiting A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors June 26, 2023 January 14, 2027
NCT05179824 Recruiting Tempus Priority Study: A Pan-tumor Observational Study October 19, 2020 October 19, 2030
NCT05445778 Recruiting Phase 3 Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) December 27, 2022 April 2029
NCT05430906 Recruiting Phase 2 AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer November 25, 2022 January 2026
NCT05025878 Recruiting 13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients. October 20, 2021 August 2023
NCT04918186 Recruiting Phase 2 Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer May 3, 2022 June 2025
NCT04507841 Recruiting Phase 2 Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer July 1, 2020 July 1, 2023
NCT06337084 Recruiting Phase 1 Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors April 10, 2024 June 2025
NCT05183984 Recruiting Phase 2 Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer February 1, 2022 February 2030
NCT03755739 Recruiting Phase 2/Phase 3 Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors November 1, 2018 November 1, 2033
NCT04679064 Recruiting Phase 3 Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment December 1, 2020 January 1, 2025
NCT05489211 Recruiting Phase 2 Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) September 6, 2022 August 19, 2026
NCT05364879 Recruiting N/A Prehabilitation for Ovarian Cancer Patients January 3, 2023 August 31, 2025
NCT06216496 Recruiting N/A Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer March 11, 2024 December 2026
NCT04747717 Recruiting N/A Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer October 1, 2020 October 1, 2025
NCT04354246 Recruiting Phase 1 COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies March 31, 2020 March 30, 2025
NCT04752865 Recruiting Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer February 9, 2018 June 2024
NCT02407509 Recruiting Phase 1 Phase I Trial of VS-6766 Alone and in Combination With Everolimus June 17, 2013 May 2024
NCT04038619 Recruiting Phase 1 Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients February 1, 2021 December 31, 2025
NCT06083844 Recruiting Phase 2 Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy December 12, 2023 September 30, 2027
NCT05746897 Recruiting Phase 1 A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors April 13, 2023 September 30, 2027
NCT05410028 Recruiting New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence March 3, 2022 March 3, 2026
NCT05769517 Recruiting PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES March 20, 2023 May 2, 2026
NCT05446298 Recruiting Phase 2 ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer December 22, 2022 June 30, 2026
NCT05029154 Recruiting N/A Exercise Preconditioning in Ovarian Cancer October 21, 2021 October 2024
NCT05870748 Recruiting Phase 2/Phase 3 REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 July 12, 2023 February 2026
NCT06117384 Recruiting Systems Oncology Approach to Optimize Ovarian Cancer Treatment January 1, 2022 December 31, 2027
NCT05761561 Recruiting N/A Trial of Exercise and Lifestyle in Women With Ovarian Cancer April 19, 2023 June 2027
NCT06032975 Recruiting PRO for Fighting FT in Ovarian Cancer October 30, 2023 September 1, 2027
NCT05053230 Recruiting N/A A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer September 20, 2021 September 20, 2024
NCT05358639 Recruiting Phase 1 Combination of Olaparib and Navitoclax in Women With HGSC and TNBC November 9, 2022 April 28, 2025
NCT05220033 Recruiting N/A Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer July 14, 2020 December 1, 2025
NCT05708703 Recruiting Assessing the Time Demands of Cancer November 13, 2023 December 31, 2030
NCT05740956 Recruiting Phase 1 A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors June 9, 2023 October 1, 2026
NCT03045965 Recruiting N/A Hysterectomy and OPPortunistic SAlpingectomy June 1, 2017 December 2053
NCT02754115 Recruiting An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy April 2016 January 2027
NCT05225428 Recruiting N/A Video Education With Result Dependent dIsclosure August 4, 2022 September 1, 2026
NCT04787289 Recruiting Phase 2 A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer September 10, 2021 January 31, 2025
NCT05537844 Recruiting Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma October 27, 2021 April 27, 2025
NCT05891171 Recruiting Phase 1 Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers October 13, 2023 August 2025
NCT05601752 Recruiting Phase 2 ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3) June 26, 2023 August 12, 2026
NCT04921527 Recruiting Phase 3 Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer December 20, 2021 July 31, 2025
NCT05265117 Recruiting The Efficacy of Hyperthermic Intraperitoneal Chemotherapy to Ovarian Cancer Patients With Homologous Recombination Repair Defect and Residual: a Prospective Cohort Study April 1, 2022 March 30, 2025
NCT06390995 Recruiting Phase 1/Phase 2 A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors May 20, 2024 September 30, 2026
NCT05043922 Recruiting Phase 2 A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma August 13, 2021 June 30, 2023
NCT05633342 Recruiting Project CADENCE (CAncer Detected Early caN be CurEd) July 7, 2022 May 2025
NCT05251883 Recruiting A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics January 1, 2022 December 2026
NCT06298877 Recruiting N/A Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer March 11, 2024 March 28, 2029
NCT04339140 Recruiting Phase 2 Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer June 24, 2020 December 31, 2024
NCT06281860 Recruiting Phase 1 Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration November 24, 2023 February 1, 2026
NCT02732860 Recruiting Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host December 2015 January 4, 2025
NCT05103683 Recruiting Phase 1 First in Human Study of TORL-1-23 in Participants With Advanced Cancer November 17, 2021 November 15, 2025
NCT05810701 Recruiting N/A FRAGINOC Study: Screening and Geriatric Assessment and Intervention in Older Patients With Epithelial Ovarian Cancer February 1, 2023 December 31, 2027
NCT06234423 Recruiting Phase 1 A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors February 9, 2024 August 31, 2027
NCT04214210 Recruiting N/A The DIALOGUE Study: Swiss-Korean Billateral Collaboration April 15, 2022 December 31, 2024
NCT02672098 Recruiting Phase 1 Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer July 14, 2016 April 2025
NCT05104515 Recruiting Phase 1 First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine November 1, 2021 December 31, 2024
NCT00005095 Recruiting Specimen and Data Study for Ovarian Cancer Early Detection and Prevention March 2000 December 2040
NCT04878094 Recruiting Phase 3 A Study of Intra-operative Imaging in Women With Ovarian Cancer May 3, 2021 May 3, 2025
NCT04701645 Recruiting Phase 1 Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer November 1, 2022 June 2026
NCT05842629 Recruiting Improved Diagnosis of Ovarian Cancer May 15, 2021 December 2028
NCT05973487 Recruiting Phase 1 A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors May 6, 2024 December 30, 2026
NCT06171789 Recruiting Phase 1/Phase 2 PRO1107 in Patients With Advanced Solid Tumors January 29, 2024 February 2027
NCT04805333 Recruiting Phase 1 Phase 1 Dose Escalation of ArtemiCoffee March 26, 2021 December 2024
NCT03772028 Recruiting Phase 3 Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) January 1, 2020 April 1, 2026
NCT05797168 Recruiting Phase 1/Phase 2 Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors June 5, 2023 November 1, 2027
NCT06052852 Recruiting Phase 1/Phase 2 Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies October 11, 2023 March 2028
NCT03275194 Recruiting Phase 2 HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy September 2, 2017 December 1, 2026
NCT05620654 Recruiting Phase 1 A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin December 1, 2022 May 1, 2023
NCT03452774 Recruiting SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry January 1, 2018 June 2027
NCT05960630 Recruiting N/A MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer October 2, 2023 December 31, 2024
NCT05057013 Recruiting Phase 1/Phase 2 HMBD-001 in Advanced HER3 Positive Solid Tumours November 10, 2021 September 2026
NCT05824247 Recruiting A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer April 1, 2022 June 1, 2025
NCT05514028 Recruiting Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin May 4, 2022 April 2026
NCT06395844 Recruiting Phase 1/Phase 2 Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer May 1, 2024 December 31, 2026
NCT05914974 Recruiting Immunotherapy-related CRP Kinetics in Metastatic Gynecological Malignancies September 11, 2023 April 2035
NCT05255471 Recruiting Phase 3 MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. January 21, 2022 January 21, 2028
NCT05964361 Recruiting Phase 1/Phase 2 First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients December 6, 2023 September 1, 2025
NCT05796973 Recruiting Phase 3 Measuring Oncological Value of Exercise and Statin March 31, 2023 December 31, 2027
NCT05787587 Recruiting Phase 1 A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors April 5, 2023 September 2025
NCT04260802 Recruiting Phase 1/Phase 2 A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers October 6, 2020 September 30, 2026
NCT05926336 Recruiting Phase 4 The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action May 23, 2023 July 2026
NCT05123482 Recruiting Phase 1/Phase 2 A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies October 18, 2021 December 30, 2025
NCT04044859 Recruiting Phase 1 ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) August 20, 2019 April 30, 2037
NCT04590326 Recruiting Phase 1/Phase 2 A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 December 9, 2020 April 27, 2027
NCT05162846 Recruiting N/A Methods for Increasing Genetic Testing Uptake in Michigan April 21, 2022 December 31, 2026
NCT06019923 Recruiting Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer October 26, 2023 September 10, 2027
NCT06203106 Recruiting NYSCF Scientific Discovery Biobank November 10, 2022 November 10, 2045
NCT04815408 Recruiting Phase 2 PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer April 1, 2021 April 1, 2025
NCT06109545 Recruiting Doppler Ultrasound and CT Versus Laparoscopy in Assessment of Ovarian Malignancy June 24, 2023 June 1, 2025
NCT00539162 Recruiting N/A Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women July 2, 2001 November 30, 2028
NCT05170594 Recruiting Phase 2 A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer December 24, 2021 June 30, 2024
NCT05255861 Recruiting An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy March 1, 2022 December 31, 2024
NCT05394675 Recruiting Phase 1 A Study of DS-9606a in Patients With Advanced Solid Tumors May 31, 2022 February 19, 2026
NCT06290193 Recruiting Phase 2 Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery February 23, 2024 February 23, 2029
NCT03831230 Recruiting Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response March 7, 2019 August 2029
NCT05776355 Recruiting N/A NKG2D CAR-NK & Ovarian Cancer March 2023 September 2024
NCT02429700 Recruiting Phase 3 TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors April 2015 May 2030
NCT05233982 Recruiting Phase 2 MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer December 9, 2021 January 2026
NCT04714957 Recruiting PITCHER (Peritoneal Carcinomatosis Heterogeneity) September 1, 2020 September 2027
NCT05410015 Recruiting Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer February 3, 2022 February 3, 2026
NCT05912972 Recruiting Development and Management of Registry in Patients With Gynecologic Cancer in Korea October 21, 2022 October 21, 2027
NCT06010875 Recruiting Phase 1 A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors November 30, 2023 September 30, 2026
NCT05848648 Recruiting PPK Study Based on Quantitative Pharmacology in Patients With Pamipril May 1, 2023 June 1, 2026
NCT06276491 Recruiting Phase 1 Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors April 4, 2024 December 2028
NCT05862740 Recruiting N/A ULTRA-LAP Trial: Laparoscopic Debulking Surgery (LDS) in Advanced Ovarian Cancer January 2, 2022 December 31, 2027
NCT05585281 Recruiting Phase 2 A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy July 27, 2023 December 22, 2025
NCT05453825 Recruiting Phase 2 A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors August 5, 2022 December 15, 2024
NCT05579366 Recruiting Phase 1/Phase 2 PRO1184 for Advanced Solid Tumors December 7, 2022 April 2026
NCT06339827 Recruiting N/A ASk Questions in GYnecologic Oncology (ASQ-GYO) April 4, 2024 May 2027
NCT06293898 Recruiting Phase 1 Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors February 9, 2024 August 24, 2027
NCT03943316 Recruiting Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies December 2, 2015 December 31, 2027
NCT05683418 Recruiting Phase 1 A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors February 15, 2023 December 2025
NCT06065358 Recruiting N/A Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response Prediction September 13, 2021 December 13, 2023
NCT03321188 Recruiting Phase 2 Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients December 15, 2017 December 15, 2024
NCT04512209 Recruiting N/A Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology October 11, 2019 December 31, 2025
NCT03017573 Recruiting N/A Prospective Biobanking Study in Ovarian, Breast, Head and Neck and Cervical Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) January 6, 2017 January 6, 2031
NCT05401162 Recruiting N/A Chemotherapy Supported by Autologous Hematopoietic Stem Cells April 15, 2022 May 2027
NCT06445621 Recruiting Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test May 30, 2024 May 2026
NCT04789694 Recruiting Phase 3 Prehabilitation in Gynaecological Cancer Patients January 25, 2021 June 30, 2026
NCT06161493 Recruiting Phase 1 ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors January 23, 2024 December 31, 2029
NCT05610501 Recruiting Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. May 1, 2021 April 30, 2024
NCT05918042 Recruiting A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation June 21, 2023 January 25, 2025
NCT05252390 Recruiting Phase 1/Phase 2 NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors March 29, 2022 November 2026
NCT06036810 Recruiting N/A Spanish Decision Tool for Ovarian Cancer Maintenance Therapy August 31, 2023 October 31, 2027
NCT05185947 Recruiting Phase 2 Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer October 13, 2022 December 30, 2031
NCT02429687 Recruiting Phase 3 TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors April 2015 May 2030
NCT05366881 Recruiting cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease May 3, 2022 December 2026
NCT04553926 Recruiting 'OLAP' (OLAparib Regulatory Post-marketing Surveillance) February 1, 2021 June 30, 2025
NCT05568680 Recruiting Phase 1 SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma March 30, 2023 March 30, 2026
NCT05735080 Recruiting Phase 1/Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer March 28, 2023 June 2026
NCT05344950 Recruiting Connecting Audio and Radio Sensing Systems to Improve Care at Home March 21, 2022 July 2025
NCT05827523 Recruiting Phase 3 Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (KOV-HIPEC-04) May 31, 2023 December 31, 2030
NCT05184140 Recruiting N/A Mapping Sentinel Lymph Node in Initial Stages of Ovarian Cancer January 1, 2021 May 1, 2023
NCT06129968 Recruiting Transforming Ovarian Cancer Diagnostic Pathways January 23, 2024 July 31, 2025
NCT05523804 Recruiting Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer August 26, 2022 December 31, 2024
NCT05377996 Recruiting Phase 1 A Study of XMT-1660 in Participants With Solid Tumors August 15, 2022 May 2027
NCT04533763 Recruiting N/A Living WELL: A Web-Based Program for Ovarian Cancer Survivors September 30, 2020 January 31, 2026
NCT05804370 Recruiting Phase 3 Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302) May 30, 2024 May 2026
NCT05145569 Recruiting Phase 2 Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer May 10, 2024 January 31, 2028
NCT05591131 Recruiting N/A Genetic Testing in African Americans April 20, 2023 November 2027
NCT04826198 Recruiting Phase 1/Phase 2 Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months October 5, 2020 October 2023
NCT06028724 Recruiting A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN) May 26, 2023 May 31, 2030
NCT05021562 Recruiting A Study of Niraparib in Patients With Ovarian Cancer in Clinical Practice September 13, 2021 March 31, 2026
NCT05009082 Recruiting Phase 3 Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer September 13, 2022 September 2030
NCT06024109 Recruiting Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy March 19, 2024 January 2026
NCT04028479 Recruiting The Registry of Oncology Outcomes Associated With Testing and Treatment May 5, 2021 October 1, 2031
NCT05252416 Recruiting Phase 1/Phase 2 (VELA) Study of BLU-222 in Advanced Solid Tumors April 7, 2022 September 30, 2026
NCT05645510 Recruiting LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study November 24, 2022 May 30, 2025
NCT05174377 Recruiting CADx - Radiomics to Distinguish the Origin of Ovarian Tumors April 5, 2021 August 1, 2025
NCT03860272 Recruiting Phase 1 Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer April 1, 2019 December 2026
NCT06232122 Recruiting N/A Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer August 1, 2022 July 31, 2028
NCT03675893 Recruiting Phase 2 RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer December 24, 2018 August 1, 2029
NCT05080946 Recruiting Early Phase 1 Using Aspirin to Improve Immunological Features of Ovarian Tumors November 2, 2021 May 2025
NCT04375956 Recruiting Phase 2 Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients April 26, 2021 June 15, 2025
NCT05815862 Recruiting Phase 2 Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer February 15, 2023 December 2024
NCT05551208 Recruiting Phase 2 Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi August 15, 2022 August 30, 2029
NCT00753480 Suspended Phase 1 A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer September 2008
NCT05708924 Suspended Phase 1 MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer April 28, 2023 September 30, 2028
NCT03275298 Suspended Evolution of the Therapeutic Care in Ovarian Cancer From 2011 April 1, 2017 December 31, 2024
NCT01218490 Suspended Phase 3 Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer December 9, 2008 May 2026
NCT05506800 Suspended Guangzhou Women's Health Cohort Study (GWHCS) March 3, 2016 August 21, 2026
NCT02432378 Suspended Phase 1/Phase 2 Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines September 4, 2015 June 1, 2026
NCT05124743 Suspended HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors September 24, 2021 May 28, 2028
NCT03393962 Suspended Phase 1/Phase 2 Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors December 1, 2017 December 2020
NCT02093871 Suspended Phase 1 A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer August 2013 June 2018
NCT03842865 Temporarily not available Expanded Access of Vigil in Solid Tumors
NCT06065059 Terminated Phase 1/Phase 2 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors December 8, 2023 May 22, 2024
NCT00085384 Terminated Phase 1/Phase 2 PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer July 2002 April 2007
NCT01485874 Terminated Phase 1 Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer November 2011 December 2015
NCT01747239 Terminated Phase 2 Cabazitaxel in Platinum Refractory Ovarian Cancer January 2013 July 2014
NCT00758732 Terminated Phase 2 Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma October 2005 March 2011
NCT02346955 Terminated Phase 1 Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) February 2015 February 2017
NCT02661815 Terminated Phase 1 A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer June 15, 2016 July 28, 2017
NCT03641287 Terminated N/A The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors December 5, 2018 September 30, 2022
NCT00897806 Terminated Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer February 2002 February 2009
NCT01175967 Terminated Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer June 2010 May 2015
NCT00418574 Terminated Phase 2/Phase 3 Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients December 2006 June 2011
NCT02432690 Terminated Phase 2 A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation June 2015 January 2, 2017
NCT01511055 Terminated Phase 2 Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand January 2012 June 2014
NCT00102622 Terminated Phase 1 Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer December 1, 2004 July 2012
NCT03286062 Terminated Phase 1 VM110 in Detection of Microscopic Tumors: A Phase I Study October 12, 2017 April 3, 2020
NCT00023907 Terminated Phase 2 Paclitaxel in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer July 2001
NCT02470585 Terminated Phase 3 Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer June 29, 2015 October 5, 2023
NCT00003382 Terminated Phase 1 Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer May 1998
NCT01096381 Terminated Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor March 2010 August 2011
NCT00006356 Terminated Phase 3 Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer August 2000
NCT01690468 Terminated Phase 1/Phase 2 PTX-200 and Carboplatin in Ovarian Cancer September 2014 December 2019
NCT00652899 Terminated Phase 2 Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer March 2008 August 2009
NCT02110277 Terminated N/A Photoacoustic Imaging of the Ovary March 2014 May 2016
NCT05061537 Terminated Phase 1 Study of PF-07263689 in Participants With Selected Advanced Solid Tumors October 20, 2021 October 14, 2022
NCT00866723 Terminated Phase 2 Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer March 2009 June 2012
NCT00373217 Terminated Phase 2 Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer April 13, 2006 February 7, 2008
NCT00086632 Terminated Phase 2 Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment July 2004 December 2007
NCT02933073 Terminated Phase 1 Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma November 2016 August 2022
NCT04598321 Terminated Phase 1 BrUOG 390: Neoadjuvant Treatment With Talazoparib March 29, 2021 December 6, 2022
NCT00050375 Terminated Phase 3 Clinical Trial for Ovarian Cancer (OvaRex®) December 2002 December 2007
NCT01170650 Terminated Phase 3 Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) April 22, 2011 September 8, 2015
NCT01284075 Terminated N/A The Effect of Guided Imagery and Music Therapy on Post-Operative Recovery After Gynecological Oncology Surgery April 2010 April 2013
NCT02452424 Terminated Phase 1/Phase 2 A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors July 2, 2015 October 12, 2018
NCT04999605 Terminated Phase 1/Phase 2 A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer June 24, 2021 June 10, 2022
NCT00574951 Terminated Phase 2 AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer December 2007
NCT00322881 Terminated Phase 2 Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer April 2006 April 2010
NCT00720096 Terminated N/A Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan July 2008 October 2009
NCT00003926 Terminated Phase 1 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors November 1998 August 2003
NCT03621982 Terminated Phase 1 Study of ADCT-301 in Patients With Selected Advanced Solid Tumors November 9, 2018 December 14, 2022
NCT00179725 Terminated Phase 1/Phase 2 Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma November 2005 June 2007
NCT00926107 Terminated Phase 2 Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse June 2009 October 2011
NCT02417753 Terminated Phase 2 AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites April 3, 2015 April 7, 2016
NCT02469116 Terminated Phase 2 Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma January 2006 March 2010
NCT00053833 Terminated Phase 2 S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer April 2003 July 2004
NCT03146663 Terminated Phase 2 NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer September 28, 2017 December 31, 2019
NCT03134638 Terminated Phase 1 A Study of SY-1365 in Adult Patients With Advanced Solid Tumors May 12, 2017 June 24, 2020
NCT04731441 Terminated N/A Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact March 18, 2021 December 1, 2023
NCT01583686 Terminated Phase 1/Phase 2 CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer May 4, 2012 December 17, 2018
NCT00418093 Terminated Phase 2 Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma September 2006 October 2011
NCT03858166 Terminated Phase 4 Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer December 1, 2017 December 31, 2020
NCT03427073 Terminated Phase 1 A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours April 27, 2015 March 13, 2017
NCT00002478 Terminated Phase 2 Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer June 1993
NCT00526799 Terminated Phase 1/Phase 2 Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer September 2007 August 2010
NCT01296035 Terminated Phase 2 Panitumumab and Gemcitabine in Relapsed Ovarian Cancer February 2011 November 2013
NCT01991210 Terminated Phase 2 A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC) February 6, 2014 August 17, 2016
NCT03149549 Terminated Phase 1/Phase 2 PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors June 1, 2017 September 10, 2020
NCT00522301 Terminated Phase 2 Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission July 2007 March 2008
NCT02218502 Terminated N/A Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses September 2014 October 1, 2015
NCT00505661 Terminated Phase 2 Letrozole in Patients With Ovarian Tumors September 2003 May 2010
NCT00253461 Terminated Early Phase 1 11C Topotecan PET Imaging December 2004 November 2009
NCT01133756 Terminated Phase 1/Phase 2 E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125 March 2010 September 2012
NCT03323398 Terminated Phase 1/Phase 2 Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies August 15, 2017 August 18, 2021
NCT03587129 Terminated Phase 2 Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer July 10, 2018 June 14, 2020
NCT03300843 Terminated Phase 2 Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer April 11, 2018 September 16, 2019
NCT02718417 Terminated Phase 3 Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) May 19, 2016 May 16, 2019
NCT01035658 Terminated Phase 1/Phase 2 Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma January 2010 March 2014
NCT04586335 Terminated Phase 1 Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. September 28, 2020 February 15, 2023
NCT00550654 Terminated Phase 2 Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain October 2007 May 2010
NCT01821859 Terminated Phase 2 Abraxane/Bevacizumab January 2010 November 2011
NCT01743547 Terminated N/A The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study November 2012 November 2013
NCT01212887 Terminated Phase 1 Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer August 2007 April 2010
NCT01202890 Terminated Phase 1 Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer September 2010 May 2012
NCT00900068 Terminated Blood Samples From Patients on a Clinical Trial to CINV During HSCT August 2008 October 2009
NCT00748527 Terminated Phase 2 Carboplatin With or Without Decitabine in Treating Patients With Progressive, Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer July 2007 November 2010
NCT02411565 Terminated Early Phase 1 Fermented Wheat Germ Extract in Women With Ovarian Cancer March 1, 2016 January 8, 2018
NCT00023634 Terminated Phase 1 S0114 Vaccine Therapy in Treating Patients With Gastric, Prostate, or Ovarian Cancer June 2001 November 2008
NCT00331422 Terminated Phase 2 Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer October 2005 March 2009
NCT01149434 Terminated Phase 1/Phase 2 Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers September 2010 August 2012
NCT00903630 Terminated Phase 1/Phase 2 Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer April 2009 August 2011
NCT02558348 Terminated Phase 1/Phase 2 Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) November 2015 May 30, 2017
NCT04267939 Terminated Phase 1 ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer February 26, 2020 December 1, 2023
NCT02978222 Terminated Phase 2 Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer July 20, 2017 January 15, 2020
NCT02669914 Terminated Phase 2 MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors September 12, 2016 January 11, 2018
NCT03944902 Terminated Phase 1 CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients September 1, 2021 January 5, 2022
NCT01281254 Terminated Phase 3 AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) April 18, 2011 April 19, 2017
NCT02326844 Terminated Phase 2 BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment March 2, 2015 April 14, 2016
NCT00288275 Terminated Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer July 2004 October 2012
NCT02769546 Terminated Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis January 2016 January 2018
NCT04244552 Terminated Phase 1 A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies February 11, 2020 November 1, 2023
NCT00539968 Terminated Phase 1/Phase 2 A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) June 2007 December 2009
NCT02203513 Terminated Phase 2 A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer January 20, 2015 August 27, 2021
NCT01010334 Terminated N/A Comparison of Standard of Care or Treatment on Protocol March 2009 July 2011
NCT02367352 Terminated Phase 1 Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors March 19, 2015 May 23, 2017
NCT01972516 Terminated Phase 2 Tivozanib As Maintenance Therapy In GYN November 2013 January 2016
NCT03549000 Terminated Phase 1 A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. July 18, 2018 October 17, 2022
NCT00287482 Terminated N/A Essiac (ESIAK) Versus Placebo to Improve Quality of Life in Transition in Women With Breast or Ovarian Cancer. October 2005 July 2007
NCT00055432 Terminated Phase 2 Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer
NCT00669422 Terminated ChemoFx® PRO - A Post-Market Data Collection Study October 2006 October 2012
NCT04691375 Terminated Phase 1 A Study of PY314 in Subjects With Advanced Solid Tumors October 29, 2020 September 22, 2023
NCT03128294 Terminated Long Term Survivors in Ovarian Cancer January 2017 December 31, 2018
NCT00738699 Terminated Phase 2 An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer September 2008 January 2012
NCT00819169 Terminated Phase 1/Phase 2 QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors January 2009 October 2011
NCT02539719 Terminated Phase 1 Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer August 2015 January 2, 2019
NCT00637390 Terminated Phase 1 A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. March 2008 October 2010
NCT04367467 Terminated Effect of PARP Inhibitors on Glomerular Filtration Rate February 3, 2020 July 1, 2021
NCT00516841 Terminated Phase 2 A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer August 2007 April 2008
NCT04891185 Terminated Phase 2 Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer October 1, 2021 October 1, 2023
NCT04814875 Terminated Phase 1/Phase 2 A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy September 1, 2021 November 30, 2023
NCT00408070 Terminated Phase 2 Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer October 2006 October 2009
NCT05261490 Terminated Phase 1/Phase 2 Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer August 1, 2022 February 15, 2024
NCT00194935 Terminated Phase 2 Weekly Topotecan Therapy in Patients With Ovarian Cancer February 2003 August 2006
NCT01016054 Terminated Phase 1 A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer October 2009 April 2010
NCT02042885 Terminated Phase 1/Phase 2 A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer January 2014 February 2015
NCT01003938 Terminated Phase 2 Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer August 2009 December 2012
NCT00862836 Terminated Phase 1/Phase 2 Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) April 2009 September 2010
NCT01227941 Terminated Phase 1 MK-4827 in Combination With Pegylated Liposomal Doxorubicin in Participants With Advanced Solid Tumors and Ovarian Cancer (MK-4827-011) November 2010 September 2011
NCT00317434 Terminated Phase 1 Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer November 2005 April 2007
NCT00003852 Terminated Phase 2 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors March 1998 March 2000
NCT01744821 Terminated N/A Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer October 2012 April 2015
NCT02278783 Terminated Phase 2 Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer March 2015 January 2017
NCT00354601 Terminated Phase 2 Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer January 2006 July 2008
NCT04460807 Terminated Phase 3 Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer February 13, 2020 April 27, 2023
NCT00003880 Terminated Phase 2/Phase 3 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer February 1999 August 2001
NCT02948426 Terminated Phase 1 Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer February 8, 2017 September 29, 2020
NCT01144442 Terminated N/A WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer July 27, 2010 May 1, 2015
NCT00585052 Terminated Phase 2 A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer August 2003 June 2013
NCT05363605 Terminated Phase 1/Phase 2 A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours April 20, 2022 September 8, 2023
NCT02649673 Terminated Phase 1 LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies March 23, 2016 July 30, 2021
NCT00651716 Terminated T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant December 2006 October 2019
NCT00003378 Terminated Phase 1 Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer August 1998
NCT00523809 Terminated Phase 2 Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor August 2007 October 2011
NCT00006262 Terminated Phase 2 Rebeccamycin Analogue in Treating Patients With Refractory Stage III or Stage IV Ovarian Epithelial Cancer July 2000 September 2001
NCT03144661 Terminated Phase 1 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies May 25, 2017 June 10, 2020
NCT00596544 Terminated Sexual Functioning After Primary Treatment of Ovarian Cancer November 2004 November 2015
NCT00898781 Terminated Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer November 2007 April 2010
NCT01312389 Terminated Phase 1/Phase 2 A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer April 2011 August 17, 2012
NCT00946283 Terminated N/A Lactobacillus in Preventing Infection in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Myelodysplastic Syndrome March 2010 October 14, 2015
NCT00287859 Terminated Phase 1 Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer August 2004 December 2006
NCT02476955 Terminated Phase 1 Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole June 9, 2015 May 7, 2019
NCT02628535 Terminated Phase 1 Safety Study of MGD009 in B7-H3-expressing Tumors September 2015 November 25, 2019
NCT04614051 Terminated Phase 1 Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) March 30, 2021 May 10, 2022
NCT03992131 Terminated Phase 1/Phase 2 A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) June 28, 2019 April 22, 2022
NCT03203993 Terminated China Ovarian Cancer BRCA Testing Study January 31, 2018 March 31, 2020
NCT04163094 Terminated Phase 1 Ovarian Cancer Treatment With a Liposome Formulated mRNA Vaccine in Combination With (Neo-)Adjuvant Chemotherapy November 25, 2019 June 26, 2023
NCT00324324 Terminated Phase 3 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant May 2006 December 2012
NCT00006812 Terminated Phase 2 Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer March 2001
NCT00189579 Terminated Phase 2 Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Patients With Ovarian Cancer January 2007
NCT00840450 Terminated Phase 2 Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian Origin April 2007 October 2012
NCT03585764 Terminated Phase 1 MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer October 24, 2018 March 26, 2024
NCT00788125 Terminated Phase 1/Phase 2 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors September 3, 2008 July 30, 2022
NCT02576665 Terminated Phase 1 A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) July 2016 December 20, 2019
NCT00003794 Terminated Quality-of-Life Study of Patients With Previously Treated Ovarian Cancer April 1999
NCT00006099 Terminated Phase 1 Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer August 2, 2000 August 12, 2002
NCT01881451 Terminated Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer August 2013 May 2020
NCT02055690 Terminated Phase 1/Phase 2 PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer September 2014 November 24, 2017
NCT01392352 Terminated Phase 2 HYPAZ: Hypertension Induced by Pazopanib April 2011 September 2015
NCT01535157 Terminated Phase 1/Phase 2 Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer February 2012 June 2017
NCT00442598 Terminated Phase 2 Safety and Efficacy Study of Glufosfamide in Ovarian Cancer January 2007 April 2008
NCT00536523 Terminated Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer April 2007 December 2009
NCT00856453 Terminated N/A Yoga in Relieving Fatigue in Patients Undergoing Chemotherapy for Ovarian Cancer May 2009 October 2009
NCT01177501 Terminated Phase 1 Trial of High Dose Topotecan With Carboplatin in Patients With Relapsed Ovarian Carcinoma April 2009 March 2012
NCT01383408 Terminated Phase 2 Distinction Between Lung Cancer and Gynecological Cancers by Canine Scent Detection March 2011 March 2013
NCT02389985 Terminated Phase 1/Phase 2 A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer July 2015 October 18, 2018
NCT00003380 Terminated Phase 1 Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer May 1998
NCT00005612 Terminated Phase 1/Phase 2 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer August 1999 February 2004
NCT01493505 Terminated Phase 3 TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer January 2012 December 2016
NCT04025216 Terminated Phase 1 A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers October 10, 2019 December 2, 2022
NCT00582205 Terminated Phase 2 Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma January 2006 December 2011
NCT00082212 Terminated Phase 2 A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma November 2004 June 2007
NCT00017134 Terminated N/A Fenretinide Followed by Surgery Compared With Surgery Alone in Preventing Ovarian Cancer in Patients at Increased Risk September 2002
NCT00602446 Terminated Phase 2 Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant August 2007 December 2009
NCT00910000 Terminated Phase 1/Phase 2 Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer June 2009 October 2015
NCT04408599 Terminated Phase 1/Phase 2 A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors June 10, 2020 July 7, 2023
NCT00004037 Terminated Phase 2 Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer June 1998
NCT01685255 Terminated Phase 2 A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy August 2012 October 23, 2014
NCT02387125 Terminated Phase 1 Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 February 28, 2015 March 29, 2019
NCT01083537 Terminated Phase 1/Phase 2 Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction February 2010 June 2012
NCT00531778 Terminated NYU Ovarian Cancer Early Detection Program Blood and Genetics June 2004 November 2010
NCT00084448 Terminated Phase 2 Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer April 2004
NCT00303888 Terminated Phase 1 Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer May 2006 October 2009
NCT03622931 Terminated Phase 2 Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines February 1, 2014 January 17, 2019
NCT00003624 Terminated Phase 2 Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer December 1998
NCT02341118 Terminated Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome. May 2014 May 8, 2023
NCT03642132 Terminated Phase 3 Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100) July 19, 2018 December 22, 2021
NCT02607813 Terminated Phase 1 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations January 18, 2016 February 19, 2022
NCT00005029 Terminated Phase 2 Topotecan in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer February 2000
NCT00653328 Terminated Phase 2 Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma May 2003 March 2009
NCT03342417 Terminated Phase 2 Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients February 14, 2018 May 29, 2019
NCT00002819 Terminated Phase 3 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer November 1996
NCT04396340 Terminated Phase 1 First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b May 11, 2020 September 30, 2022
NCT01137071 Terminated Phase 2 Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer April 2011 June 2015
NCT00003386 Terminated Phase 2 Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer July 1999
NCT04254107 Terminated Phase 1 A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer May 29, 2020 December 1, 2023
NCT05395052 Terminated Phase 1 FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors May 31, 2022 August 11, 2023
NCT00849667 Terminated Phase 3 Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse April 16, 2009 April 12, 2013
NCT00277290 Terminated Phase 2 Study of XL999 in Patients With Previously Treated Ovarian Cancer January 2006 November 2006
NCT04377087 Terminated Phase 2 Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer June 29, 2020 May 31, 2023
NCT04875806 Terminated Phase 1/Phase 2 A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors June 30, 2021 January 30, 2024
NCT00583622 Terminated Phase 2 Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients December 2007 January 2012
NCT03799913 Unknown status Early Phase 1 MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer April 10, 2019 April 2022
NCT03846856 Unknown status The IGF Axis Involvement in Immune Tumor Microenvironment in Ovarian Cancer and Its Clinical Significance April 2019 March 2021
NCT03916679 Unknown status Phase 1/Phase 2 MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer April 20, 2019 April 20, 2023
NCT03648489 Unknown status Phase 2 Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) September 21, 2018 December 2022
NCT04089189 Unknown status Phase 2 Study of IMP4297 in Patients With BRCA1/2 Mutation Ovarian Cancer September 11, 2019 August 2022
NCT03863860 Unknown status Phase 3 A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients April 30, 2019 December 31, 2022
NCT02719041 Unknown status Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study April 2016 April 2018
NCT00155896 Unknown status Establishing the Incidences of BRCA1 and BRCA2 Mutation by Combining DHPLC and Direct Sequencing in Ovarian Cancer January 2003 December 2008
NCT00327925 Unknown status Blood Test for Ovarian Cancer Associated Antibodies (CAAb) July 2006 June 2008
NCT01187706 Unknown status A Controlled Study of Quality of Life and it's Related Factors Among Gynecological Cancer Survivors August 2010
NCT00722228 Unknown status Phase 1/Phase 2 Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors July 2008 January 2022
NCT00003733 Unknown status Phase 2 Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer December 1997
NCT00039559 Unknown status N/A Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer May 2002 December 2014
NCT04503980 Unknown status Early Phase 1 αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors March 26, 2020 June 2022
NCT00419627 Unknown status Proteomic Analysis of HLA Complex in Solid Cancers: Breast, Ovary, Colon, Rectum, Stomach, and Pancreas February 2007
NCT02188550 Unknown status Phase 2 Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer June 2014
NCT00703105 Unknown status Phase 2 Ovarian Dendritic Cell Vaccine Trial October 2008 July 2021
NCT01242072 Unknown status Phase 1 Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies November 2010 December 2012
NCT00238342 Unknown status N/A Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass October 2005
NCT02952183 Unknown status N/A Efficacy of Pelvic Autonomic Nerve Monitoring System (PAMS I) in Female Patients With Pelvic Tumors July 2015
NCT00004206 Unknown status Phase 2 Oxaliplatin and Fluorouracil in Treating Patients With Recurrent Ovarian Cancer September 1999
NCT01220154 Unknown status Phase 1 Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer October 2010
NCT04849858 Unknown status Phase 3 Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures May 20, 2019 June 2022
NCT03076372 Unknown status Phase 1 A Study Evaluating MM-310 in Patients With Solid Tumors February 22, 2017 December 2018
NCT00003718 Unknown status Phase 2 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma September 1998
NCT00005025 Unknown status Phase 2 Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer June 2000
NCT02178462 Unknown status Biomarkers for Gynecologic Cancer June 2014 March 2018
NCT04176484 Unknown status Feasibility of Opportunistic Salpingectomy During Non-Gynecologic Surgery December 1, 2019 December 1, 2022
NCT00017303 Unknown status Phase 2 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer January 2001
NCT04383977 Unknown status Phase 2 Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer May 2020 June 2021
NCT03709316 Unknown status Phase 3 A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer June 30, 2018 December 30, 2023
NCT00155935 Unknown status N/A The Development of Human Immunologic Assays Specific to Folate Receptor Antigen January 2004 December 2008
NCT00886717 Unknown status Phase 1/Phase 2 Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer May 2008
NCT02821793 Unknown status Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer January 2016 July 2020
NCT03184753 Unknown status Phase 1/Phase 2 Genetically Modified T Cells Against Ovarian Cancer May 15, 2017 December 31, 2020
NCT01187602 Unknown status Short Non-coding RNA Biomarkers of Predisposition to Ovarian Cancer August 2010 June 2015
NCT05273944 Unknown status Phase 1 Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients July 28, 2021 April 30, 2022
NCT05371301 Unknown status Phase 3 Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer July 16, 2021 December 2023
NCT01268956 Unknown status Circulating Lymphatic Progenitor Cell and Lymph Node Metastasis January 2011 September 2011
NCT03210298 Unknown status International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) January 2016 September 2022
NCT03154281 Unknown status Phase 1 Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast July 17, 2017 June 2024
NCT04812938 Unknown status Exploiting Pathogenic Tp53 Mutation for Early Diagnosis of Ovarian Cancer by Mean of Papanicolau Test April 12, 2021 October 1, 2022
NCT04582552 Unknown status The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer December 15, 2020 November 2023
NCT04229615 Unknown status Phase 3 A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy June 2, 2020 April 1, 2024
NCT00036712 Unknown status Phase 2 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation January 2002
NCT03219242 Unknown status N/A Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology June 30, 2016 January 30, 2018
NCT01100372 Unknown status Phase 2 Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer July 2009
NCT04528940 Unknown status Tumor Grade Determines PD-1/PDL-1 Expression August 25, 2020 September 30, 2021
NCT00002477 Unknown status Phase 3 Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer April 1991
NCT02349958 Unknown status Phase 2 Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy September 2006 January 2022
NCT02534922 Unknown status Phase 1 Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer February 2016 February 2019
NCT04337632 Unknown status Phase 3 Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer August 1, 2017 June 2021
NCT03019315 Unknown status The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients January 2015 December 2020
NCT03547375 Unknown status Phase 2 Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy June 1, 2018 June 1, 2020
NCT01387399 Unknown status Phase 1 Safety and Pharmacokinetics of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) With Cisplatin to Treat Platinum-sensitive Recurrent Ovarian Cancer June 2011 July 2013
NCT03448354 Unknown status N/A Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer October 26, 2017 July 1, 2022
NCT01470235 Unknown status Hypodontia and Ovarian Cancer September 2011 August 2015
NCT01715168 Unknown status Phase 1 A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer October 2012 December 2015
NCT03362606 Unknown status Phase 1/Phase 2 Engineered Immune Effectors Against Ovarian Cancer November 15, 2017 December 2020
NCT01465750 Unknown status Epidemiology of Ovarian Cancer in Taiwan April 2011 April 2014
NCT02686463 Unknown status N/A Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy April 2016 June 2023
NCT01600573 Unknown status Phase 1/Phase 2 Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ) May 2012 March 2017
NCT04300699 Unknown status N/A Feasibility of Frailty Assessment and Implementation of Interventions in Women Over 70 With Epithelial Ovarian Cancer June 1, 2020 December 1, 2022
NCT00726635 Unknown status Phase 3 The Assessment of Preoperative Psychological Intervention on Stress in Women With Gynecological Malignancies August 2008 August 2009
NCT04489706 Unknown status N/A Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 Mutation June 28, 2020 November 2022
NCT04566952 Unknown status Phase 2 Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer October 28, 2020 October 1, 2023
NCT05342506 Unknown status Phase 2 Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies April 18, 2022 May 31, 2024
NCT01770535 Unknown status Oxford Ovarian Cancer Predict Chemotherapy Response 01 November 2012 June 2015
NCT00757263 Unknown status Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom February 2008
NCT04055038 Unknown status Phase 2/Phase 3 Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) September 1, 2019 January 1, 2022
NCT00003634 Unknown status Phase 2 Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy April 1998
NCT04714931 Unknown status N/A Sentinel Lymph Node Assessment in Ovarian Cancer (TRSGO-SLN-OO5) January 1, 2021 April 1, 2022
NCT01367353 Unknown status N/A Characterization of Ovarian Cancer Stem Cell January 2010 December 2013
NCT03979339 Unknown status N/A Feasibility of a New Technology for Isolating Circulating Tumour Cells March 11, 2020 December 2023
NCT03539328 Unknown status Phase 2 Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer June 2018 April 2022
NCT03556566 Unknown status Phase 2 Open Label Immunotherapy Trial for Ovarian Cancer July 1, 2018 December 31, 2019
NCT03638206 Unknown status Phase 1/Phase 2 Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies March 1, 2018 March 1, 2023
NCT00905658 Unknown status Phase 2 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer June 2008
NCT00533299 Unknown status Phase 3 Hydralazine Valproate for Ovarian Cancer August 2007 December 2009
NCT03399344 Unknown status N/A Clinical Impact of Dedicated MR Staging of Ovarian Cancer April 13, 2018 July 1, 2022
NCT02457650 Unknown status Phase 1 T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies April 2015 December 2019
NCT05069818 Unknown status Variance of HRD From Paired Ovarian Cancer October 2021 December 2022
NCT00897039 Unknown status Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer March 2006
NCT01334437 Unknown status Blood Test for Ovarian Cancer Associated Auto Antibodies June 2012 January 2015
NCT01258881 Unknown status Retrospective Study of Ovarian Cancer Patients With Brain Metastasis April 2010 December 2011
NCT00173394 Unknown status The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients August 2005 December 2008
NCT04170712 Unknown status Data and Specimen Bank of Patients Diagnosed With, and at High-risk for, Gynecologic Cancers June 10, 2016 June 10, 2022
NCT03942068 Unknown status Phase 2 Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer September 1, 2019 December 30, 2020
NCT03278717 Unknown status Phase 3 Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients June 15, 2018 December 2023
NCT03895788 Unknown status Phase 1 A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer January 14, 2019 March 2020
NCT00499512 Unknown status Role of Spirituality in Coping and Surviving With Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer August 10, 2005 August 31, 2020
NCT04627740 Unknown status Phase 1/Phase 2 Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer December 1, 2020 December 31, 2023
NCT04000295 Unknown status Phase 3 Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer August 16, 2019 July 2022
NCT02704832 Unknown status Phase 3 Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE) March 2016 February 2021
NCT03763123 Unknown status Phase 1 A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. April 24, 2018 December 31, 2020
NCT02458001 Unknown status N/A Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer July 2015 March 2017
NCT01388621 Unknown status Phase 2 Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer October 2011 July 2015
NCT00002487 Unknown status Phase 2 Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer July 1991
NCT00410462 Unknown status Phase 2 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma October 2006
NCT02970786 Unknown status Phase 1 Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans November 2016
NCT00004064 Unknown status Phase 2 Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer November 1998
NCT04590625 Unknown status Phase 2 Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer October 2020 December 2023
NCT05274867 Unknown status Development of a Patient Reported Outcome Measure for Advanced Ovarian Cancer Patients Receiving Surgical and Chemotherapy Treatment March 7, 2022 June 7, 2022
NCT04696276 Unknown status N/A Implementing Enhanced Recovery After Surgery (ERAS) Pathways In Major Gynecologic Oncology Operations In Greece January 6, 2020 December 30, 2021
NCT01570582 Unknown status Phase 2 A Phase IIclinical Trial of Carboplatin and Paclitaxel or Carboplatin and Gemcitabine in Platinum-sensitive, Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer March 2010 March 2014
NCT03283943 Unknown status Phase 1 PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. April 1, 2018 December 16, 2020
NCT04295577 Unknown status Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR February 3, 2020 February 3, 2024
NCT00982631 Unknown status Phase 1 A Study of Combination of Temsirolimus (Torisel®) and Pegylated Liposomal Doxorubicin (PLD, Doxil®/Caelyx®) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer June 2009 August 2012
NCT00003160 Unknown status Phase 2 Weekly Infusions of Paclitaxel in Treating Women With Stage III or Stage IV Ovarian Cancer Refractory to Paclitaxel and Platinum September 1997
NCT00003560 Unknown status Phase 2 Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer May 1998
NCT03959761 Unknown status Phase 1/Phase 2 Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma July 31, 2019 November 30, 2021
NCT04402333 Unknown status Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival June 26, 2020 October 3, 2021
NCT02480790 Unknown status Venous Thromboembolic Complications in Ovarian Cancer November 2014 September 2019
NCT02132988 Unknown status Phase 2 Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer November 2013 November 2018
NCT00155740 Unknown status Mesothelin as a New Tumor Marker for Ovarian Cancer January 2002 December 2006
NCT05175326 Unknown status Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs November 1, 2021 November 1, 2022
NCT03235648 Unknown status N/A Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer June 1, 2017 June 1, 2023
NCT00045461 Unknown status Phase 2/Phase 3 Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer June 2000
NCT03371693 Unknown status Phase 3 Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer September 30, 2017 March 30, 2023
NCT02247323 Unknown status Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125 January 2016 December 2021
NCT00854399 Unknown status N/A Screening and Identification of Ovarian Cancers January 2006 December 2011
NCT03446495 Unknown status An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer March 28, 2017 May 20, 2019
NCT00511641 Unknown status Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer February 12, 2002 February 2021
NCT02545010 Unknown status Phase 1 Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer September 2015 August 2018
NCT00021385 Unknown status Phase 2 Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer May 2001
NCT01889615 Unknown status Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer August 2013 January 2017
NCT03808792 Unknown status Imaging Study in Advanced Ovarian Cancer January 2020 December 31, 2022
NCT00436774 Unknown status Treatment Outcome and Quality of Life in Patients With Pediatric Extra-Cranial Germ Cell Tumors Previously Treated on Clinical Trial CCLG-GC-1979-01 or CCLG-GC-1989-01 June 2006
NCT00652119 Unknown status Phase 1 Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin February 2008 August 2021
NCT00003064 Unknown status Phase 1/Phase 2 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Persistent Epithelial Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer January 1997
NCT00595348 Unknown status Korean Hereditary Breast Cancer Study November 2007 May 2017
NCT01180504 Unknown status Phase 2 Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer August 2010 August 2016
NCT04911114 Unknown status N/A Targeted Physical Activity to Improve Mobility and Falls Risk in Women Living With Ovarian Cancer June 15, 2021 December 31, 2022
NCT01654146 Unknown status Phase 3 ICON8: Weekly Chemotherapy in Ovarian Cancer June 2011
NCT04473339 Unknown status Phase 3 A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation August 1, 2020 December 30, 2023
NCT05044091 Unknown status Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients September 15, 2021 September 2023
NCT03298074 Unknown status Phase 2 Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer October 2017 April 2019
NCT00075543 Unknown status Phase 1/Phase 2 Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer July 2003
NCT03000192 Unknown status HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life August 2016 September 2021
NCT02684318 Unknown status Phase 1/Phase 2 Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors July 2015 October 2019
NCT04217798 Unknown status Phase 2 Efficacy and Safety of Niraparib Combined With Oral Etoposide in Platinum Resistant/Refractory Recurrent Ovarian Cancer May 21, 2020 June 1, 2022
NCT00003135 Unknown status Phase 2 Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer November 1997
NCT01888159 Unknown status N/A Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve September 2013
NCT01267851 Unknown status Clinical Database and Biobank of Patients With Gynecologic Neoplasms January 1, 2010 December 30, 2020
NCT00551122 Unknown status Phase 1/Phase 2 Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors November 2006
NCT02711865 Unknown status Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer May 2016 May 2019
NCT00305838 Unknown status Phase 2 CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen March 2004
NCT00855998 Unknown status Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer March 2009 March 2011
NCT03393507 Unknown status Phase 2 A Study of Apatinib Treatment in for Advanced Ovarian Cancer August 1, 2017 December 1, 2019
NCT02433626 Unknown status Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies December 2015 June 2020
NCT01074398 Unknown status Biomarkers in Predicting Response in Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Treated on GOG-0172 or GOG-0182 February 2010
NCT00463996 Unknown status MRI in Staging Ovarian Cancer Using MRI Contrast Agent April 2007 April 2008
NCT00527631 Unknown status Phase 1 Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer July 2006 November 2012
NCT02321735 Unknown status N/A DOD Long-Term Survivors of Ovarian Cancer September 2014 September 2019
NCT03335241 Unknown status Phase 2 Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer March 1, 2017 December 2022
NCT03188159 Unknown status Phase 2 Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer July 1, 2017 July 1, 2022
NCT03814447 Unknown status Early Phase 1 The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer August 16, 2019 January 2023
NCT04053114 Unknown status MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii September 2019 May 2020
NCT00004115 Unknown status Phase 3 Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy December 1998
NCT02638402 Unknown status Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers May 2016 August 2017
NCT00601406 Unknown status N/A Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer March 2006
NCT01779128 Unknown status Early Phase 1 PET-CT vs. Integrated MR-PET Scanning of GYN Cancers March 2013
NCT00553683 Unknown status Phase 1/Phase 2 Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer October 2007 July 2014
NCT02225015 Unknown status Phase 1 Cancer Prevention in Women With a BRCA Mutation January 2015 June 2019
NCT03517332 Unknown status Circulating Tumor DNA Exposure in Peripheral Blood January 1, 2015 December 31, 2019
NCT00274950 Unknown status Phase 3 Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors May 2005
NCT00838656 Unknown status Phase 2 Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer October 2007
NCT00964626 Unknown status Phase 2 Paclitaxel and Cisplatin as First-Line Treatment for Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer April 2009
NCT03738319 Unknown status Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer November 10, 2018 November 23, 2019
NCT00854282 Unknown status N/A The Role of Regulatory T Cell in Ovarian Cancer: Focus on Relationship Between Clinical Prognosis and Regulatory T Cell Expression January 2009 December 2012
NCT00276718 Unknown status N/A Etoposide, Carboplatin, and Bleomycin in Treating Young Patients Undergoing Surgery For Malignant Germ Cell Tumors April 1989
NCT03924882 Unknown status Phase 2 Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer April 25, 2019 April 25, 2022
NCT00772798 Unknown status Phase 2 A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer June 2007 June 2009
NCT04661696 Unknown status Phase 2 Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer. December 9, 2020 February 23, 2024
NCT04235556 Unknown status Integrated Care Pathway in Oncology (PASSION) February 21, 2020 December 31, 2022
NCT04169997 Unknown status Phase 3 A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer December 24, 2019 December 30, 2022
NCT04280185 Unknown status N/A HIPEC in the Treatment of Stage IIc-IV Epithelial Ovarian Cancer After CRS (HIPECOC) June 1, 2020 May 1, 2024
NCT00532194 Unknown status Phase 3 An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer July 2007 December 2016
NCT01823731 Unknown status A Pilot Test for Newly Developed Synoptic Operative Template for Ovarian Cancer (SOTOC): National Cancer Center - Peritoneal Carcinomatosis Index January 2013 December 2013
NCT01087268 Unknown status Phase 3 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer January 2009
NCT04617470 Unknown status Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study July 8, 2020 January 1, 2022
NCT03150992 Unknown status N/A EDMONd - Elemental Diet in Bowel Obstruction July 19, 2017 December 2019
NCT00900289 Unknown status Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer March 2002
NCT03526809 Unknown status Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology June 1, 2016 December 31, 2019
NCT03634501 Unknown status Phase 1/Phase 2 Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer(NK)Cells October 26, 2018 September 30, 2022
NCT04368130 Withdrawn N/A SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care September 1, 2022 September 1, 2023
NCT03032614 Withdrawn Phase 2 Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients September 30, 2017 April 30, 2020
NCT04542603 Withdrawn Phase 1 Neuroinflammation and Age-associated Brain Pathology: Two Potential Mechanisms of Cognitive Impairment in Ovarian Cancer June 2025 August 2026
NCT04102436 Withdrawn Phase 2 Non-Viral TCR Gene Therapy March 8, 2024 March 8, 2024
NCT00408967 Withdrawn Phase 2 Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. December 31, 2006 May 31, 2008
NCT00017537 Withdrawn Phase 1 Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer March 2000 March 2005
NCT02713984 Withdrawn Phase 1/Phase 2 A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer March 2016 July 2019
NCT03806049 Withdrawn Phase 3 Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer December 2019 December 2024
NCT04941378 Withdrawn Phase 1 OTL38 Injection (OTL38) for Intra-Operative Imaging of Folate Receptor Positive Ovarian Cancer May 28, 2022 May 28, 2022
NCT01624493 Withdrawn Phase 1/Phase 2 BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients October 2012 October 2014
NCT00006267 Withdrawn Phase 2 Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
NCT01766622 Withdrawn Phase 2 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant November 30, 2012 July 24, 2013
NCT01661868 Withdrawn Phase 2 Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer August 2012 August 2012
NCT00084370 Withdrawn N/A Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy June 2002 March 2005
NCT02667925 Withdrawn N/A Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin March 2016 September 2016
NCT00562185 Withdrawn Phase 1/Phase 2 Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer May 2008 March 2009
NCT03933761 Withdrawn Phase 2 Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy July 29, 2019 August 2, 2021
NCT00484666 Withdrawn Platinum-Resistant, Recurrent Epithelial Ovarian Cancer May 2006 May 2009
NCT00787488 Withdrawn N/A Pilot Study of IV and IP Chemotherapy Plus Abdominal Hyperthermia for Ovarian Ca April 2009 April 2009
NCT00753740 Withdrawn Phase 2 Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients. September 2008 May 2010
NCT01131039 Withdrawn Phase 2 Safety and Efficacy Study of Gemcitabine Plus Bevacizumab in Patients With Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer January 2011 September 2011
NCT02117817 Withdrawn Phase 1 Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer February 2015 February 25, 2015
NCT00085527 Withdrawn Phase 2 FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer May 2005 September 2005
NCT00369954 Withdrawn Phase 2 Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin April 2006
NCT00842582 Withdrawn Phase 1 Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer February 2009 March 2011
NCT00813254 Withdrawn Cost Utility Analysis in Recurrent Ovarian Cancer December 2008 January 2011
NCT01386502 Withdrawn Phase 1 CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors June 15, 2011 October 31, 2011
NCT04464967 Withdrawn Phase 1/Phase 2 Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers March 2021 February 2023
NCT03644459 Withdrawn Phase 1 Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 April 3, 2019 August 2020
NCT00005645 Withdrawn Phase 2 ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment May 1999
NCT03281681 Withdrawn Phase 1/Phase 2 A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer March 2021 September 2022
NCT05201001 Withdrawn Phase 2 APX005M in Patients With Recurrent Ovarian Cancer September 7, 2023 September 7, 2023
NCT01097239 Withdrawn Phase 1/Phase 2 Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer November 2009 September 2018
NCT04602117 Withdrawn Phase 1 ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer July 28, 2021 November 17, 2021
NCT03905902 Withdrawn Phase 3 DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma August 2021 August 16, 2021
NCT01606358 Withdrawn Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer
NCT00080639 Withdrawn CA-125 in Screening Patients at High Risk for Ovarian Cancer June 2003 June 2007
NCT02017678 Withdrawn Phase 2 Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin January 2014 June 2015
NCT02836028 Withdrawn Phase 2 A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer October 2016
NCT01880996 Withdrawn Phase 1/Phase 2 Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies August 2014 August 2015
NCT00460200 Withdrawn Depression and Interleukin-6 Production in Patients With Ovarian Epithelial Cancer December 2003
NCT05905341 Withdrawn Phase 1 Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. January 15, 2024 April 13, 2028
NCT00693342 Withdrawn Phase 3 Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
NCT00323726 Withdrawn Trends in Incidence and Survivals for Ovarian Germ Cell Tumors: A 27-Year Population-Based Study December 2005 December 2006
NCT04239014 Withdrawn Phase 2 A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. August 7, 2020 January 25, 2021
NCT04795596 Withdrawn Phase 2/Phase 3 Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers April 1, 2021 April 9, 2022
NCT00477867 Withdrawn N/A Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172
NCT03197584 Withdrawn Phase 1/Phase 2 QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy December 2017 April 2019
NCT00634894 Withdrawn Phase 2 Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer March 2008 September 2008
NCT00603460 Withdrawn Phase 1/Phase 2 DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer January 2012 March 2013
NCT05431582 Withdrawn Phase 1 Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors December 14, 2022 December 14, 2022
NCT00003865 Withdrawn Phase 2 Toremifene in Treating Patients With Ovarian Cancer July 22, 1999 February 22, 2017
NCT00118300 Withdrawn Phase 1 Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer April 2005
NCT02083536 Withdrawn Phase 1 LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma May 2014
NCT00093678 Withdrawn N/A Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
NCT00610792 Withdrawn Phase 2 Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens July 2006
NCT01017809 Withdrawn N/A Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian Cancer December 2010 December 2013
NCT00173407 Withdrawn N/A PTEN and IGFBP-3 Correlation in Ovarian Carcinoma Invasion January 2006 October 2012
Disase is a (Disease Ontology)
DOID:120
Cross Reference ID (Disease Ontology)
GARD:7295
Cross Reference ID (Disease Ontology)
ICD10CM:C56
Cross Reference ID (Disease Ontology)
ICD9CM:183.0
Cross Reference ID (Disease Ontology)
MESH:D010051
Cross Reference ID (Disease Ontology)
MIM:167000
Cross Reference ID (Disease Ontology)
MIM:607893
Cross Reference ID (Disease Ontology)
NCI:C4984
Cross Reference ID (Disease Ontology)
NCI:C7431
Cross Reference ID (Disease Ontology)
ORDO:213500
Cross Reference ID (Disease Ontology)
ORDO:213517
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:123843001
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:372117006
Cross Reference ID (Disease Ontology)
SNOMEDCT_US_2023_03_01:93934004
Cross Reference ID (Disease Ontology)
UMLS_CUI:C0919267
Cross Reference ID (Disease Ontology)
UMLS_CUI:C1140680
Cross Reference ID (Disease Ontology)
UMLS_CUI:C1299247
Exact Synonym (Disease Ontology)
malignant Ovarian tumor
Exact Synonym (Disease Ontology)
malignant tumour of ovary
Exact Synonym (Disease Ontology)
ovarian neoplasm
Exact Synonym (Disease Ontology)
ovary neoplasm
Exact Synonym (Disease Ontology)
primary ovarian cancer
Exact Synonym (Disease Ontology)
tumor of the Ovary